<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="58ce42c6-10bd-4bb4-bf89-eae8ed82c339"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use DASATINIB TABLETS safely and effectively. See full prescribing information for DASATINIB TABLETS. <br/>
      <br/> DASATINIB tablets, for oral use <br/> Initial U.S. Approval: 2006</title>
   <effectiveTime value="20240803"/>
   <setId root="58ce42c6-10bd-4bb4-bf89-eae8ed82c339"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="650082092"/>
            <name>Aurobindo Pharma Limited</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="872201704" root="1.3.6.1.4.1.519.1"/>
                        <name>EUGIA Pharma Specialities Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-542" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-543" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-544" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-545" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-546" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-547" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-542" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-543" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-544" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-545" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-546" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-547" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-542" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-543" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-544" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-545" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-546" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-547" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4cedc2fa-a09d-4ebb-bbe1-8683144b59c9"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240803"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59651-542" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DASATINIB<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DASATINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RBZ1571X5H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DASATINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="X78UG0A0RN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DASATINIB ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T9FYH5QMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 101</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X7XJ6RM9Q2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 112</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59651-542-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250422"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="59651-542-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250422"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216547" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250422"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>White to off-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="6"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;20</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59651-543" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DASATINIB<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DASATINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="50" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RBZ1571X5H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DASATINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="X78UG0A0RN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DASATINIB ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T9FYH5QMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 101</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X7XJ6RM9Q2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 112</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59651-543-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250422"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="59651-543-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250422"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216547" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250422"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>White to off-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="11"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;50</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59651-544" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DASATINIB<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DASATINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="70" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RBZ1571X5H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DASATINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="X78UG0A0RN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DASATINIB ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T9FYH5QMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 101</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X7XJ6RM9Q2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 112</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59651-544-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250422"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="59651-544-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250422"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216547" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250422"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>White to off-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="9"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;70</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59651-545" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DASATINIB<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DASATINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="80" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RBZ1571X5H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DASATINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="X78UG0A0RN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DASATINIB ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T9FYH5QMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 101</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X7XJ6RM9Q2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 112</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59651-545-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250422"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="59651-545-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250422"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216547" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250422"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>White to off-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48353" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRIANGLE">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="10"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;80</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59651-546" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DASATINIB<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DASATINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RBZ1571X5H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DASATINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="X78UG0A0RN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DASATINIB ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T9FYH5QMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 101</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X7XJ6RM9Q2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 112</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59651-546-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250422"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="59651-546-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250422"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216547" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250422"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>White to off-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="15"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;100</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59651-547" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DASATINIB<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DASATINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="140" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RBZ1571X5H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DASATINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="X78UG0A0RN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DASATINIB ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T9FYH5QMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 101</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X7XJ6RM9Q2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 112</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59651-547-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250422"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="59651-547-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250422"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216547" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250422"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>White to off-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="11"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;140</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="06cb21ad-906b-47a6-8f86-5ec26122b235"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Dasatinib tablets are indicated for the treatment of adult patients with</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.</item>
                     <item> chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.</item>
                     <item> Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.</item>
                  </list>
                  <paragraph>
                     <content styleCode="italics">Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240803"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Dasatinib tablets are a kinase inhibitor indicated for the treatment of</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (<linkHtml href="#Section_1">1</linkHtml>, <linkHtml href="#Section_14">14</linkHtml>)</item>
                           <item>adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (<linkHtml href="#Section_1">1</linkHtml>, <linkHtml href="#Section_14">14</linkHtml>)</item>
                           <item>adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (<linkHtml href="#Section_1">1</linkHtml>, <linkHtml href="#Section_14">14</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="50bec111-74e6-4bc8-b6b5-2cfd02b7583c"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240803"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Chronic phase CML in adults: 100 mg once daily. (<linkHtml href="#Section_2">2</linkHtml>)</item>
                           <item>Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg once daily. (<linkHtml href="#Section_2">2</linkHtml>)</item>
                           <item>Administer orally, with or without a meal. Do not crush, cut, or chew tablets. (<linkHtml href="#Section_2">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="63c7f873-abb4-4e8c-a6c8-180e20b047cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1 Dosage of Dasatinib Tablets in Adult Patients</title>
                     <text>
                        <paragraph>The recommended starting dosage of dasatinib tablets for chronic phase CML in adults is 100 mg administered orally once daily. The recommended starting dosage of dasatinib tablets for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults is 140 mg administered orally once daily. Tablets should not be crushed, cut, or chewed; they should be swallowed whole. Dasatinib tablets can be taken with or without a meal, either in the morning or in the evening.</paragraph>
                        <br/>
                        <paragraph>Refer to Section 2.4 for recommendations on dose escalation in adults with CML and Ph+ ALL.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="9de0a2e9-4097-45db-b161-92ae663862f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.3 Dose Modification</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Strong CYP3A4 Inducers</content>
                        </paragraph>
                        <paragraph>Avoid the use of concomitant strong CYP3A4 inducers and St. John’s wort. If patients must be coadministered a strong CYP3A4 inducer, consider a dasatinib tablets dose increase. If the dose of dasatinib tablets is increased, monitor the patient carefully for toxicity <content styleCode="italics">[see <linkHtml href="#Section_7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Strong CYP3A4 Inhibitors</content>
                        </paragraph>
                        <paragraph>Avoid the use of concomitant strong CYP3A4 inhibitors and grapefruit juice. Recommend selecting an alternate concomitant medication with no or minimal enzyme inhibition potential, if possible. If dasatinib tablets must be administered with a strong CYP3A4 inhibitor, consider a dose decrease to:</paragraph>
                        <br/>
                        <list listType="unordered" styleCode="disc">
                           <item>40 mg daily for patients taking dasatinib tablets 140 mg daily.</item>
                           <item>20 mg daily for patients taking dasatinib tablets 100 mg daily.</item>
                        </list>
                        <paragraph>These reduced doses of dasatinib tablets are predicted to adjust the area under the curve (AUC) to the range observed without CYP3A4 inhibitors; however, clinical data are not available with these dose adjustments in patients receiving strong CYP3A4 inhibitors. If dasatinib tablets is not tolerated after dose reduction, either discontinue the strong CYP3A4 inhibitor or interrupt dasatinib tablets until the inhibitor is discontinued. Allow a washout period of approximately 1 week after the inhibitor is stopped before the dasatinib tablets dose is increased <content styleCode="italics">[see <linkHtml href="#Section_7.1">Drug Interactions (7.1)</linkHtml>]</content>.<br/>
                           <content styleCode="italics">
                              <br/> Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="32c6a0c9-612f-43a6-b859-e965dc5b3b13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.4 Dose Escalation in Adults with CML and Ph+ ALL</title>
                     <text>
                        <paragraph>For adult patients with CML and Ph+ ALL, consider dose escalation to 140 mg once daily (chronic phase CML) or 180 mg once daily (advanced phase CML and Ph+ ALL) in patients who do not achieve a hematologic or cytogenetic response at the recommended starting dosage. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="37f284ff-7f4f-413c-8409-b1afd388f9a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.5 Dose Adjustment for Adverse Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Myelosuppression</content>
                        </paragraph>
                        <paragraph>In clinical studies, myelosuppression was managed by dose interruption, dose reduction, or discontinuation of study therapy. Hematopoietic growth factor has been used in patients with resistant myelosuppression. Guidelines for dose modifications for adult patients are summarized in Table 3.</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 3: Dose Adjustments for Neutropenia and Thrombocytopenia in Adults 
			</caption>
                           <colgroup>
                              <col width="33.32%"/>
                              <col width="33.32%"/>
                              <col width="33.34%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="11">*ANC: absolute neutrophil count</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="3" align="center" valign="middle">Chronic Phase CML<br/>(starting dose 100 mg<br/>once daily)<br/>
                                 </td>
                                 <td styleCode="Rrule" rowspan="3" align="center" valign="middle">ANC* &lt;0.5 × 109/L<br/>or<br/>Platelets &lt;50 × 109/L<br/>
                                 </td>
                                 <td styleCode="Rrule" align="justify" valign="top">1. Stop dasatinib tablets until ANC ≥1.0 × 109/L and platelets ≥50 × 109/L.<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="top">2. Resume treatment with dasatinib tablets at the original starting dose if recovery occurs in ≤7 days.<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="top">3. If platelets &lt;25 × 109/L or recurrence of ANC &lt;0.5 × 109/L for &gt;7 days, repeat Step 1 and resume dasatinib tablets at a reduced dose of 80 mg once daily for second episode. For third episode, further reduce dose to 50 mg once daily (for newly diagnosed patients) or discontinue dasatinib tablets (for patients resistant or intolerant to prior therapy including imatinib).<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="4" align="center" valign="middle">Accelerated Phase CML,<br/>Blast Phase CML and<br/>Ph+ ALL<br/>(starting dose 140 mg<br/>once daily)<br/>
                                 </td>
                                 <td styleCode="Rrule" rowspan="4" align="center" valign="middle">ANC* &lt;0.5 × 109/L<br/>or<br/>Platelets &lt;10 × 109/L<br/>
                                 </td>
                                 <td styleCode="Rrule" align="justify" valign="top">1. Check if cytopenia is related to leukemia (marrow aspirate or biopsy).<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="top">2. If cytopenia is unrelated to leukemia, stop dasatinib tablets until ANC ≥1.0 × 109/L and platelets ≥20 × 109/L and resume at the original starting dose.<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="top">3. If recurrence of cytopenia, repeat Step 1 and resume dasatinib tablets at a reduced dose of 100 mg once daily (second episode) or 80 mg once daily (third episode).<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="justify" valign="top">4. If cytopenia is related to leukemia, consider dose escalation to 180 mg once daily.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">
                              <br/> Non-Hematologic Adverse Reactions</content>
                        </paragraph>
                        <br/>
                        <paragraph>For adults with Ph+ CML and ALL, if a severe non-hematologic adverse reaction develops with dasatinib tablets use, treatment must be withheld until the adverse reaction has resolved or improved. Thereafter, treatment can be resumed as appropriate at a reduced dose depending on the severity and recurrence <content styleCode="italics">[see <linkHtml href="#Section_5">Warnings and Precautions (5)</linkHtml>]</content>.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.5">
                     <id root="575c4f09-06ab-4f88-9dd8-5c289d1fe277"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.6 Duration of Treatment</title>
                     <text>
                        <paragraph>In clinical studies, treatment with dasatinib tablets in adult patients with chronic phase CML was continued until disease progression or until no longer tolerated by the patient. The effect of stopping treatment on long-term disease outcome after the achievement of a cytogenetic response (including complete cytogenetic response [CCyR]) or major molecular response (MMR and MR4.5) has not been established.<br/>
                           <br/> Dasatinib tablets is a hazardous product. Follow applicable special handling and disposal procedures.<sup>1</sup>
                           <br/>
                           <content styleCode="italics">
                              <br/> Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="ec54a01f-edad-4b02-bb31-acb62b262572"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Dasatinib tablets are available as 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg white to off-white, biconvex, film-coated tablets.</paragraph>
               </text>
               <effectiveTime value="20240803"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. (<linkHtml href="#Section_3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="a074dca4-5823-4c31-938c-fc64efe0ea35"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20240803"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#Section_4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="eb4aec22-54cf-45c2-a1b9-2dcbdf8762b8"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240803"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Myelosuppression and Bleeding Events: </content>Severe thrombocytopenia, neutropenia, and anemia may occur. Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. Monitor complete blood counts regularly. Transfuse and interrupt dasatinib when indicated. (<linkHtml href="#Section_2.4">2.5</linkHtml>, <linkHtml href="#Section_5.1">5.1</linkHtml>, <linkHtml href="#Section_5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Fluid Retention:</content> Fluid retention, sometimes severe, including pleural effusions. Manage with supportive care measures and/or dose modification. (<linkHtml href="#Section_2.4">2.5</linkHtml>, <linkHtml href="#Section_5.3">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Cardiovascular Toxicity:</content> Monitor patients for signs or symptoms and treat appropriately. (<linkHtml href="#Section_5.4">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Pulmonary Arterial Hypertension (PAH): </content>Dasatinib may increase the risk of developing PAH which may be reversible on discontinuation. Consider baseline risk and evaluate patients for signs and symptoms of PAH during treatment. Stop dasatinib if PAH is confirmed. (<linkHtml href="#Section_5.5">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">QT Prolongation:</content> Use dasatinib with caution in patients who have or may develop prolongation of the QT interval. (<linkHtml href="#Section_5.6">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Severe Dermatologic Reactions:</content> Individual cases of severe mucocutaneous dermatologic reactions have been reported. (<linkHtml href="#Section_5.7">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Tumor Lysis Syndrome:</content> Tumor lysis syndrome has been reported. Maintain adequate hydration and correct uric acid levels prior to initiating therapy with dasatinib. (<linkHtml href="#Section_5.8">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Embryo-Fetal Toxicity:</content> Can cause fetal harm. Advise patients of reproductive potential of potential risk to fetus and to use effective contraception. (<linkHtml href="#Section_5.9">5.9</linkHtml>, <linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Effects on Growth and Development in Pediatric Patients:</content> epiphyses delayed fusion, osteopenia, growth retardation, and gynecomastia have been reported. Monitor bone growth and development in pediatric patients. (<linkHtml href="#Section_5.10">5.10</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Hepatotoxicity: </content>Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. (<linkHtml href="#Section_5.11">5.11</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="98345b93-1a22-4601-8c9a-aff5c86f4488"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.1 Myelosuppression</title>
                     <text>
                        <paragraph>Treatment with dasatinib is associated with severe (NCI CTCAE Grade 3 or 4) thrombocytopenia, neutropenia, and anemia, which occur earlier and more frequently in patients with advanced phase CML or Ph+ ALL than in patients with chronic phase CML<content styleCode="italics"> [see <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                        <br/>
                        <paragraph>In patients with chronic phase CML, perform complete blood counts (CBCs) every 2 weeks for 12 weeks, then every 3 months thereafter, or as clinically indicated. In patients with advanced phase CML or Ph+ ALL, perform CBCs weekly for the first 2 months and then monthly thereafter, or as clinically indicated.</paragraph>
                        <br/>
                        <paragraph>Myelosuppression is generally reversible and usually managed by withholding dasatinib temporarily and/or dose reduction <content styleCode="italics">[see <linkHtml href="#Section_2.4">Dosage and Administration (2.5)</linkHtml>]</content>.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="8053a1a0-89ea-44b8-9941-a42a2c749ce6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.2 Bleeding-Related Events</title>
                     <text>
                        <paragraph>Dasatinib can cause serious and fatal bleeding. In all CML or Ph+ ALL clinical studies, Grade ≥3 central nervous system (CNS) hemorrhages, including fatalities, occurred in &lt;1% of patients receiving dasatinib. The incidence of Grade 3/4 hemorrhage occurred in 5.8% of adult patients and generally required treatment interruptions and transfusions. The incidence of Grade 5 hemorrhage occurred in 0.4% of adult patients. The most frequent site of hemorrhage was gastrointestinal <content styleCode="italics">[see <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Most bleeding events in clinical studies were associated with severe thrombocytopenia. In addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction <content styleCode="italics">in vitro</content>.</paragraph>
                        <br/>
                        <paragraph>Concomitant medications that inhibit platelet function or anticoagulants may increase the risk of hemorrhage.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="cef587d2-5554-44dd-8346-050caafb0a4e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.3 Fluid Retention</title>
                     <text>
                        <paragraph>Dasatinib may cause fluid retention <content styleCode="italics">[see <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml>]</content>. After 5 years of follow-up in the adult randomized newly diagnosed chronic phase CML study (n=258), Grade 3 or 4 fluid retention was reported in 5% of patients, including 3% of patients with Grade 3 or 4 pleural effusion. In adult patients with newly diagnosed or imatinib-resistant or -intolerant chronic phase CML, Grade 3 or 4 fluid retention occurred in 6% of patients treated with dasatinib at the recommended dose (n=548). In adult patients with advanced phase CML or Ph+ ALL treated with dasatinib at the recommended dose (n=304), Grade 3 or 4 fluid retention was reported in 8% of patients, including Grade 3 or 4 pleural effusion reported in 7% of patients.<br/>
                           <br/> Evaluate patients who develop symptoms of pleural effusion or other fluid retention, such as new or worsened dyspnea on exertion or at rest, pleuritic chest pain, or dry cough, promptly with a chest x-ray or additional diagnostic imaging as appropriate. Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. Severe pleural effusion may require thoracentesis and oxygen therapy. Consider dose reduction or treatment interruption <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#Section_2.4">Dosage and Administration (2.5)</linkHtml>
                           </content>
                           <content styleCode="italics">].<br/>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="italics">
                                 <br/> Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="ea57625e-d651-4fcd-a9a6-1ad5313c1ac7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.4 Cardiovascular Toxicity</title>
                     <text>
                        <paragraph>Dasatinib can cause cardiac dysfunction <content styleCode="italics">[see <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml>]</content>. After 5 years of follow-up in the randomized newly diagnosed chronic phase CML trial in adults (n=258), the following cardiac adverse reactions occurred: cardiac ischemic events (3.9% dasatinib vs 1.6% imatinib), cardiac-related fluid retention (8.5% dasatinib vs 3.9% imatinib), and conduction system abnormalities, most commonly arrhythmia and palpitations (7.0% dasatinib vs 5.0% imatinib). Two cases (0.8%) of peripheral arterial occlusive disease occurred with imatinib and 2 (0.8%) transient ischemic attacks occurred with dasatinib. Monitor patients for signs or symptoms consistent with cardiac dysfunction and treat appropriately.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="2e75dbbc-be2a-494c-a37e-288da6db5b60"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.5 Pulmonary Arterial Hypertension</title>
                     <text>
                        <paragraph>Dasatinib may increase the risk of developing pulmonary arterial hypertension (PAH) in adult and pediatric patients which may occur any time after initiation, including after more than 1 year of treatment. Manifestations include dyspnea, fatigue, hypoxia, and fluid retention <content styleCode="italics">[see <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml>]</content>. PAH may be reversible on discontinuation of dasatinib. Evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to initiating dasatinib and during treatment. If PAH is confirmed, dasatinib should be permanently discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="b08e2a6f-17b2-48a1-ba45-655d1ca1b350"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.6 QT Prolongation</title>
                     <text>
                        <paragraph>Dasatinib may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy <content styleCode="italics">[see <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Correct hypokalemia or hypomagnesemia prior to and during dasatinib administration. </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="ac8c57bd-9c91-4f12-9d41-01ee95f2beaa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.7 Severe Dermatologic Reactions</title>
                     <text>
                        <paragraph>Cases of severe mucocutaneous dermatologic reactions, including Stevens-Johnson syndrome <content styleCode="italics">[see <linkHtml href="#Section_6.3">Adverse Reactions (6.2)</linkHtml>]</content> and erythema multiforme, have been reported in patients treated with dasatinib. Discontinue permanently in patients who experience a severe mucocutaneous reaction during treatment if no other etiology can be identified.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="3d7de736-12c9-4cc7-8fa7-fa143212964e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.8 Tumor Lysis Syndrome</title>
                     <text>
                        <paragraph>Tumor lysis syndrome has been reported in patients with resistance to prior imatinib therapy, primarily in advanced phase disease. Due to potential for tumor lysis syndrome, maintain adequate hydration, correct uric acid levels prior to initiating therapy with dasatinib, and monitor electrolyte levels. Patients with advanced stage disease and/or high tumor burden may be at increased risk and should be monitored more frequently <content styleCode="italics">[see <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.9">
                     <id root="02ad7629-f8fa-4a7b-b86f-7d07570b1f42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.9 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on limited human data, dasatinib can cause fetal harm when administered to a pregnant woman. Adverse pharmacologic effects of dasatinib including hydrops fetalis, fetal leukopenia, and fetal thrombocytopenia have been reported with maternal exposure to dasatinib. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with dasatinib and for 30 days after the last dose <content styleCode="italics">[see <linkHtml href="#Section_8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.10">
                     <id root="faaf9087-3adb-4564-8461-e5f7930ac9d9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.10 Effects on Growth and Development in Pediatric Patients</title>
                     <text>
                        <paragraph>In pediatric trials of dasatinib in chronic phase CML after at least 2 years of treatment, adverse reactions associated with bone growth and development were reported in 5 (5.2%) patients, one of which was severe in intensity (Growth Retardation Grade 3). These 5 cases included cases of epiphyses delayed fusion, osteopenia, growth retardation, and gynecomastia <content styleCode="italics">[see <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#Section_8.4">Use in Specific Populations (8.4)</linkHtml>]</content>. Of these 5 cases, 1 case of osteopenia and 1 case of gynecomastia resolved during treatment. </paragraph>
                        <paragraph>Monitor bone growth and development in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.11">
                     <id root="e33c49a4-ae5e-47ab-89b9-3a7f0f1564cf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.11 Hepatotoxicity</title>
                     <text>
                        <paragraph>Dasatinib may cause hepatotoxicity as measured by elevations in bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase <content styleCode="italics">[see <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml>]</content>
                           <content styleCode="italics">.</content> Monitor transaminases at baseline and monthly or as clinically indicated during treatment. Reduce dose, withhold, or permanently discontinue dasatinib based on severity <content styleCode="italics">[see <linkHtml href="#Section_2.4">Dosage and Administration (2.5)</linkHtml>]</content>. When dasatinib is administered in combination with chemotherapy, liver toxicity in the form of transaminase elevation and hyperbilirubinemia has been observed. Monitor hepatic function when dasatinib is used in combination with chemotherapy.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="0f136305-6ed8-456f-a9fb-7e3384d9699d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Myelosuppression <content styleCode="italics">[see <linkHtml href="#Section_2.4">Dosage and Administration (2.5)</linkHtml> and <linkHtml href="#Section_5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                     <item>Bleeding-related events <content styleCode="italics">[see <linkHtml href="#Section_5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                     </item>
                     <item>Fluid retention <content styleCode="italics">[see <linkHtml href="#Section_5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                     </item>
                     <item>Cardiovascular toxicity <content styleCode="italics">[see <linkHtml href="#Section_5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                     </item>
                     <item>Pulmonary arterial hypertension <content styleCode="italics">[see <linkHtml href="#Section_5.5">Warnings and Precautions (5.5)</linkHtml>].</content>
                     </item>
                     <item>QT prolongation <content styleCode="italics">[see <linkHtml href="#Section_5.6">Warnings and Precautions (5.6)</linkHtml>].</content>
                     </item>
                     <item>Severe dermatologic reactions <content styleCode="italics">[see <linkHtml href="#Section_5.7">Warnings and Precautions (5.7)</linkHtml>].</content>
                     </item>
                     <item>Tumor lysis syndrome <content styleCode="italics">[see <linkHtml href="#Section_5.8">Warnings and Precautions (5.8)</linkHtml>].</content>
                     </item>
                     <item>Effects on growth and development in pediatric patients <content styleCode="italics">[see <linkHtml href="#Section_5.10">Warnings and Precautions (5.10)</linkHtml>]</content>. </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#Section_5">Warnings and Precautions (5.11)</linkHtml>]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20240803"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥15%) in patients receiving dasatinib as single-agent therapy included myelosuppression, fluid retention events, diarrhea, headache, skin rash, hemorrhage, dyspnea, fatigue, nausea, and musculoskeletal pain. (<linkHtml href="#Section_6">6</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc., at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="e76a68be-6f34-44b4-b7cf-7dd324c724c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <br/>
                        <paragraph>The data described below reflect exposure to dasatinib administered as single-agent therapy at all doses tested in clinical studies, including 324 adult patients with newly diagnosed chronic phase CML, and 2388 adult patients with imatinib-resistant or -intolerant chronic or advanced phase CML or Ph+ ALL. The median duration of therapy in a total of 2712 adult patients was 19.2 months (range 0 to 93.2 months). In a randomized trial in patients with newly diagnosed chronic phase CML, the median duration of therapy was approximately 60 months. The median duration of therapy in 1618 adult patients with chronic phase CML was 29 months (range 0 to 92.9 months).</paragraph>
                        <br/>
                        <paragraph>The median duration of therapy in 1094 adult patients with advanced phase CML or Ph+ ALL was 6.2 months (range 0 to 93.2 months).</paragraph>
                        <br/>
                        <paragraph>In the overall population of 2712 adult patients, 88% of patients experienced adverse reactions at some time and 19% experienced adverse reactions leading to treatment discontinuation. </paragraph>
                        <br/>
                        <paragraph>In the randomized trial in adult patients with newly diagnosed chronic phase CML, drug was discontinued for adverse reactions in 16% of patients with a minimum of 60 months of follow-up. After a minimum of 60 months of follow-up, the cumulative discontinuation rate was 39%. Among the 1618 patients with chronic phase CML, drug-related adverse reactions leading to discontinuation were reported in 329 (20.3%) patients; among the 1094 patients with advanced phase CML or Ph+ ALL, drug-related adverse reactions leading to discontinuation were reported in 191 (17.5%) patients.</paragraph>
                        <br/>
                        <paragraph>Adverse reactions reported in ≥10% of adult patients, and other adverse reactions of interest, in a randomized trial in patients with newly diagnosed chronic phase CML at a median follow-up of approximately 60 months are presented in Table 6.</paragraph>
                        <br/>
                        <paragraph>Adverse reactions reported in ≥10% of adult patients treated at the recommended dose of 100 mg once daily (n=165), and other adverse reactions of interest, in a randomized dose-optimization trial of patients with chronic phase CML resistant or intolerant to prior imatinib therapy at a median follow-up of approximately 84 months are presented in Table 8.</paragraph>
                        <br/>
                        <paragraph>Drug-related serious adverse reactions (SARs) were reported for 16.7% of adult patients in the randomized trial of patients with newly diagnosed chronic phase CML. Serious adverse reactions reported in ≥5% of patients included pleural effusion (5%).</paragraph>
                        <br/>
                        <paragraph> Drug-related SARs were reported for 26.1% of patients treated at the recommended dose of 100 mg once daily in the randomized dose-optimization trial of adult patients with chronic phase CML resistant or intolerant to prior imatinib therapy. Serious adverse reactions reported in ≥5% of patients included pleural effusion (10%).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Chronic Myeloid Leukemia (CML)</content>
                        </paragraph>
                        <paragraph>Adverse reactions (excluding laboratory abnormalities) that were reported in at least 10% of adult patients are shown in Table 6 for newly diagnosed patients with chronic phase CML and Tables 8 and 10 for CML patients with resistance or intolerance to prior imatinib therapy.<br/>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 6:  Adverse Reactions Reported in ≥10% of Adult Patients with Newly Diagnosed   Chronic Phase CML (minimum of 60 months follow-up) 
			</caption>
                           <colgroup>
                              <col width="34.74%"/>
                              <col width="15.26%"/>
                              <col width="18.32%"/>
                              <col width="11.68%"/>
                              <col width="20%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center"> <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Grade 3/4</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center"> <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Dasatinib</content>
                                    <br/>
                                    <content styleCode="bold">(n=258)</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Imatinib</content>
                                    <br/>
                                    <content styleCode="bold">(n=258)</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Dasatinib</content>
                                    <br/>
                                    <content styleCode="bold">(n=258)</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Imatinib</content>
                                    <br/>
                                    <content styleCode="bold">(n=258)</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="4" align="center">
                                    <content styleCode="bold">Percent (%) of Patients</content>
                                    <br/>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="115" align="justify">
                                    <sup>a </sup>Includes cardiac failure acute, cardiac failure congestive, cardiomyopathy, diastolic dysfunction, ejection fraction decreased, and left ventricular dysfunction.<br/>
                                    <sup>b    </sup>Includes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin exfoliation, and rash vesicular.<br/>
                                    <sup>c</sup>  Adverse reaction of special interest with &lt;10% frequency.<br/>
                                    <sup>d</sup>  Includes conjunctival hemorrhage, ear hemorrhage, ecchymosis, epistaxis, eye hemorrhage, gingival bleeding, hematoma, hematuria, hemoptysis, intra-abdominal hematoma, petechiae, scleral hemorrhage, uterine hemorrhage, and vaginal hemorrhage.<br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fluid retention<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">38<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">45<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pleural effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">28<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Superficial localized edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">38<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pulmonary hypertension<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Generalized edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pericardial effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Congestive heart failure/cardiac      dysfunction<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pulmonary edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Diarrhea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">22<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">23<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Musculoskeletal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">17<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Rash<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Headache<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Abdominal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fatigue<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Nausea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">25<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Myalgia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Arthralgia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Hemorrhage<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">    Gastrointestinal bleeding<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">    Other bleeding<sup>d</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">    CNS bleeding<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Vomiting<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Muscle spasms<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>A comparison of cumulative rates of adverse reactions reported in ≥10% of patients with minimum follow-up of 1 and 5 years in a randomized trial of newly diagnosed patients with chronic phase CML treated with dasatinib are shown in Table 7.</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 7: Adverse Reactions Reported in ≥10% of Adult Patients with Newly Diagnosed Chronic Phase CML in the Dasatinib-Treated Arm (n=258) 
			</caption>
                           <colgroup>
                              <col width="31.68%"/>
                              <col width="18.32%"/>
                              <col width="16.8%"/>
                              <col width="15.26%"/>
                              <col width="17.94%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" rowspan="3">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Minimum of 1 Year Follow-up</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Minimum of 5 Years Follow-up</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grade 3/4</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grade 3/4</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" colspan="4" align="center">
                                    <content styleCode="bold">Percent (%) of Patients</content>
                                    <br/>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="justify">
                                    <sup>a </sup> Includes cardiac failure acute, cardiac failure congestive, cardiomyopathy, diastolic dysfunction, ejection fraction decreased, and left ventricular dysfunction.<br/>
                                    <sup>b</sup>  Includes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin<br/>  exfoliation, and rash vesicular.<br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fluid retention<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">19<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">38<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pleural effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">28<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Superficial localized edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pulmonary hypertension<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Generalized edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pericardial effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Congestive heart failure/cardiac dysfunction<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pulmonary edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Diarrhea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">17<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">22<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Musculoskeletal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Rash<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Headache<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Abdominal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fatigue<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Nausea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>At 60 months, there were 26 deaths in dasatinib-treated patients (10.1%) and 26 deaths in imatinib-treated patients (10.1%); 1 death in each group was assessed by the investigator as related to study therapy.  </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 8:  Adverse Reactions Reported in ≥10% of Adult Patients with Chronic Phase   CML Resistant or Intolerant to Prior Imatinib Therapy (minimum of 84 months follow-up) 
			</caption>
                           <colgroup>
                              <col width="33.34%"/>
                              <col width="33.34%"/>
                              <col width="33.34%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" rowspan="4">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">100 mg Once Daily</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Chronic </content>
                                    <br/>
                                    <content styleCode="bold">(n=165)</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grade 3/4</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Percent (%) of Patients</content>
                                    <br/>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3"> <sup>a  </sup> Includes drug eruption, erythema, erythema multiforme, erythrosis, exfoliative rash, generalized erythema,  genital rash, heat rash, milia, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, skin exfoliation, skin irritation, urticaria vesiculosa, and rash vesicular.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fluid retention<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">48<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Superficial localized edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">22<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pleural effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">28<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Generalized edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pericardial effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pulmonary hypertension<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Headache<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">33<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Diarrhea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">28<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fatigue<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">26<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dyspnea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">24<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Musculoskeletal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">22<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Nausea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Skin rash<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Myalgia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Arthralgia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Infection (including bacterial, viral,<br/>fungal, and non-specified)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Abdominal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Hemorrhage<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Gastrointestinal bleeding<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pruritus<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Constipation<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>Cumulative rates of selected adverse reactions that were reported over time in patients treated with the 100 mg once daily recommended starting dose in a randomized dose-optimization trial of imatinib-resistant or -intolerant patients with chronic phase CML are shown in Table 9.</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 9: Selected Adverse Reactions Reported in Adult Dose Optimization Trial (Imatinib-Intolerant or -Resistant Chronic Phase CML)<sup>a</sup>
                           </caption>
                           <colgroup>
                              <col width="20.98%"/>
                              <col width="9.04%"/>
                              <col width="18.48%"/>
                              <col width="9.5%"/>
                              <col width="16.42%"/>
                              <col width="11.6%"/>
                              <col width="13.98%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" rowspan="3">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Minimum of 2 Years</content>
                                    <br/>
                                    <content styleCode="bold">Follow-up</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Minimum of 5 Years</content>
                                    <br/>
                                    <content styleCode="bold">Follow-up</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Minimum of 7 Years</content>
                                    <br/>
                                    <content styleCode="bold">Follow-up</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grade 3/4</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grade 3/4</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grade 3/4</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" colspan="6" align="center">
                                    <content styleCode="bold">Percent (%) of Patients</content>
                                    <br/>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="7" align="justify">
                                    <sup>a</sup>    Randomized dose-optimization trial results reported in the recommended starting dose of 100 mg once daily<br/>    (n=165) population.<br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Diarrhea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">27<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">28<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">28<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fluid retention<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">34<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">42<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">48<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Superficial edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">22<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pleural effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">24<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">28<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Generalized edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pericardial effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pulmonary<br/>hypertension<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Hemorrhage<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">   Gastrointestinal<br/>    bleeding<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 10:  Adverse Reactions Reported in ≥10% of Adult Patients with Advanced Phase CML Resistant or Intolerant to Prior Imatinib Therapy 
			</caption>
                           <colgroup>
                              <col width="30.16%"/>
                              <col width="9.16%"/>
                              <col width="13.74%"/>
                              <col width="10.68%"/>
                              <col width="13.74%"/>
                              <col width="10.68%"/>
                              <col width="11.84%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" rowspan="4">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="6" align="center">
                                    <content styleCode="bold">140 mg Once Daily</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Accelerated (n=157)</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Myeloid Blast (n=74)</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Lymphoid Blast (n=33)</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grade </content>
                                    <br/>
                                    <content styleCode="bold">3/4</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All </content>
                                    <br/>
                                    <content styleCode="bold">Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grade </content>
                                    <br/>
                                    <content styleCode="bold">3/4</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All </content>
                                    <br/>
                                    <content styleCode="bold">Grades</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grade </content>
                                    <br/>
                                    <content styleCode="bold">3/4</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" colspan="6" align="center">
                                    <content styleCode="bold">Percent (%) of Patients</content>
                                    <br/>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="7" align="justify">
                                    <sup>a   </sup>Includes ventricular dysfunction, cardiac failure, cardiac failure congestive, cardiomyopathy, congestive cardiomyopathy, diastolic dysfunction, ejection fraction decreased, and ventricular failure.<br/>
                                    <sup>b</sup>   Includes drug eruption, erythema, erythema multiforme, erythrosis, exfoliative rash, generalized erythema, genital rash, heat rash, milia, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, skin exfoliation, skin irritation, urticaria vesiculosa, and rash vesicular.<br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fluid retention<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">35<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">34<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Superficial localized edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pleural effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Generalized edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pericardial effusion<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Congestive heart failure/cardiac dysfunction<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Pulmonary edema<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Headache<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">27<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">15<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Diarrhea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">31<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fatigue<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">19<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dyspnea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">15<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Musculoskeletal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Nausea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">19<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">23<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Skin rash<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">15<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">16<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Arthralgia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Infection (including bacterial, viral, fungal, and non-specified)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Hemorrhage<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">26<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">19<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">24<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Gastrointestinal bleeding<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   CNS bleeding<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Vomiting<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">15<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pyrexia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Febrile neutropenia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Adverse reactions associated with bone growth and development were reported in 5 (5.2%) of pediatric patients with chronic phase CML <content styleCode="italics">[see <linkHtml href="#Section_5.10">Warnings and Precautions (5.10)</linkHtml>]</content>.<br/>
                           <content styleCode="italics">
                              <br/> Laboratory Abnormalities</content>
                        </paragraph>
                        <paragraph>Myelosuppression was commonly reported in all patient populations. The frequency of Grade 3 or 4 neutropenia, thrombocytopenia, and anemia was higher in patients with advanced phase CML than in chronic phase CML (Tables 12 and 13). Myelosuppression was reported in patients with normal baseline laboratory values as well as in patients with pre-existing laboratory abnormalities.</paragraph>
                        <br/>
                        <paragraph>In patients who experienced severe myelosuppression, recovery generally occurred following dose interruption or reduction; permanent discontinuation of treatment occurred in 2% of adult patients with newly diagnosed chronic phase CML and 5% of adult patients with resistance or intolerance to prior imatinib therapy <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                        <br/>
                        <paragraph>Grade 3 or 4 elevations of transaminases or bilirubin and Grade 3 or 4 hypocalcemia, hypokalemia, and hypophosphatemia were reported in patients with all phases of CML but were reported with an increased frequency in patients with myeloid or lymphoid blast phase CML. Elevations in transaminases or bilirubin were usually managed with dose reduction or interruption. Patients developing Grade 3 or 4 hypocalcemia during dasatinib therapy often had recovery with oral calcium supplementation.</paragraph>
                        <br/>
                        <paragraph>Laboratory abnormalities reported in adult patients with newly diagnosed chronic phase CML are shown in Table 12. There were no discontinuations of dasatinib therapy in this patient population due to biochemical laboratory parameters. </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 12:  CTC Grade 3/4 Laboratory Abnormalities in Adult Patients with Newly Diagnosed Chronic Phase CML (minimum of 60 months follow-up) 
			</caption>
                           <colgroup>
                              <col width="33.34%"/>
                              <col width="33.34%"/>
                              <col width="33.34%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" align="justify" valign="top"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Dasatinib </content>
                                    <br/>
                                    <content styleCode="bold">(n=258)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Imatinib </content>
                                    <br/>
                                    <content styleCode="bold">(n=258)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="center" valign="middle">
                                    <content styleCode="bold">Percent (%) of Patients</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Hematology Parameters</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="justify" valign="top"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="justify" valign="top"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Neutropenia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">29<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">24<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Thrombocytopenia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">22<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Anemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Biochemistry Parameters</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Hypophosphatemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">31<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Hypokalemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Hypocalcemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Elevated SGPT (ALT)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Elevated SGOT (AST)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Elevated Bilirubin<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">   Elevated Creatinine<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>CTC grades: neutropenia (Grade 3 ≥0.5 to &lt;1.0 × 10<sup>9</sup>/L, Grade 4 &lt;0.5 × 10<sup>9</sup>/L); thrombocytopenia (Grade 3 ≥25 to &lt;50 × 10<sup>9</sup>/L, Grade 4 &lt;25 × 10<sup>9</sup>/L); anemia (hemoglobin Grade 3 ≥65 to &lt;80 g/L, Grade 4 &lt;65 g/L); elevated creatinine (Grade 3 &gt;3 to 6 × upper limit of normal range (ULN), Grade 4 &gt;6 × ULN); elevated bilirubin (Grade 3 &gt;3 to 10 × ULN, Grade 4 &gt;10 × ULN); elevated SGOT or SGPT (Grade 3 &gt;5 to 20 × ULN, Grade 4 &gt;20 × ULN); hypocalcemia (Grade 3 &lt;7.0 to 6.0 mg/dL, Grade 4 &lt;6.0 mg/dL); hypophosphatemia (Grade 3 &lt;2.0 to 1.0 mg/dL, Grade 4 &lt;1.0 mg/dL); hypokalemia (Grade 3 &lt;3.0 to 2.5 mmol/L, Grade 4 &lt;2.5 mmol/L).</paragraph>
                        <br/>
                        <paragraph>Laboratory abnormalities reported in patients with CML resistant or intolerant to imatinib who received the recommended starting doses of dasatinib are shown by disease phase in Table 13. </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 13:  CTC Grade 3/4 Laboratory Abnormalities in Clinical Studies of CML in Adults: Resistance or Intolerance to Prior Imatinib Therapy 
			</caption>
                           <colgroup>
                              <col width="27.12%"/>
                              <col width="16.78%"/>
                              <col width="19.84%"/>
                              <col width="18.32%"/>
                              <col width="17.94%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" align="justify" valign="top"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Chronic Phase CML 100 mg Once Daily</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="3" align="center" valign="middle">
                                    <content styleCode="bold">Advanced Phase CML </content>
                                    <br/>
                                    <content styleCode="bold">140 mg Once Daily</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">(n=165)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Accelerated</content>
                                    <br/>
                                    <content styleCode="bold">Phase </content>
                                    <br/>
                                    <content styleCode="bold">(n=157)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Myeloid Blast</content>
                                    <br/>
                                    <content styleCode="bold">Phase </content>
                                    <br/>
                                    <content styleCode="bold">(n=74)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Lymphoid Blast</content>
                                    <br/>
                                    <content styleCode="bold">Phase </content>
                                    <br/>
                                    <content styleCode="bold">(n=33)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="5" align="center" valign="middle">
                                    <content styleCode="bold">Percent (%) of Patients</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Hematology Parameters*</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">     Neutropenia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">36<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">58<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">77<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">79<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Thrombocytopenia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">24<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">63<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">78<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">85<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Anemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">47<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">74<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">52<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Biochemistry Parameters</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Hypophosphatemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Hypokalemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">15<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Hypocalcemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Elevated SGPT (ALT)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Elevated SGOT (AST)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Elevated Bilirubin<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">   Elevated Creatinine<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>CTC grades: neutropenia (Grade 3 ≥0.5 to &lt;1.0 × 10<sup>9</sup>/L, Grade 4 &lt;0.5 × 10<sup>9</sup>/L); thrombocytopenia (Grade 3 ≥25 to &lt;50 × 10<sup>9</sup>/L, Grade 4 &lt;25 × 10<sup>9</sup>/L); anemia (hemoglobin Grade 3 ≥65 to &lt;80 g/L, Grade 4 &lt;65 g/L); elevated creatinine (Grade 3 &gt;3 to 6 × upper limit of normal range (ULN), Grade 4 &gt;6 × ULN); elevated bilirubin (Grade 3 &gt;3 to 10 × ULN, Grade 4 &gt;10 × ULN); elevated SGOT or SGPT (Grade 3 &gt;5 to 20 × ULN, Grade 4 &gt;20 × ULN); hypocalcemia (Grade 3 &lt;7.0 to 6.0 mg/dL, Grade 4 &lt;6.0 mg/dL); hypophosphatemia (Grade 3 &lt;2.0 to 1.0 mg/dL, Grade 4 &lt;1.0 mg/dL); hypokalemia (Grade 3 &lt;3.0 to 2.5 mmol/L, Grade 4 &lt;2.5 mmol/L).</paragraph>
                        <paragraph>* Hematology parameters for 100 mg once-daily dosing in chronic phase CML reflects 60-month minimum follow-up.</paragraph>
                        <br/>
                        <paragraph>Among adult patients with chronic phase CML with resistance or intolerance to prior imatinib therapy, cumulative Grade 3 or 4 cytopenias were similar at 2 and 5 years including:  neutropenia (36% vs 36%), thrombocytopenia (23% vs 24%), and anemia (13% vs 13%).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in Adults</content>
                        </paragraph>
                        <paragraph>A total of 135 adult patients with Ph+ ALL were treated with dasatinib in clinical studies. The median duration of treatment was 3 months (range 0.03 to 31 months). The safety profile of patients with Ph+ ALL was similar to those with lymphoid blast phase CML. The most frequently reported adverse reactions included fluid retention events, such as pleural effusion (24%) and superficial edema (19%), and gastrointestinal disorders, such as diarrhea (31%), nausea (24%), and vomiting (16%). Hemorrhage (19%), pyrexia (17%), rash (16%), and dyspnea (16%) were also frequently reported. Serious adverse reactions reported in ≥5% of patients included pleural effusion (11%), gastrointestinal bleeding (7%), febrile neutropenia (6%), and infection (5%).</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="a729d795-1e3a-491b-91e9-b9a6fe370632"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Additional Pooled Data from Clinical Trials</content>
                           <br/>
                           <br/> The following additional adverse reactions were reported in adult patients in dasatinib CML clinical studies and adult patients in Ph+ ALL clinical studies at a frequency of ≥10%, 1% to &lt;10%, 0.1% to &lt;1%, or &lt;0.1%. These adverse reactions are included based on clinical relevance.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gastrointestinal Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>mucosal inflammation (including mucositis/stomatitis), dyspepsia, abdominal distension, constipation, gastritis, colitis (including neutropenic colitis), oral soft tissue disorder; <content styleCode="italics">0.1% to &lt;1% – </content>ascites, dysphagia, anal fissure, upper gastrointestinal ulcer, esophagitis, pancreatitis, gastroesophageal reflux disease; <content styleCode="italics">&lt;0.1% – </content>protein losing gastroenteropathy, ileus, acute pancreatitis, anal fistula.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">General Disorders and Administration-Site Conditions: </content>
                           </content>≥<content styleCode="italics">10% – </content>peripheral edema, face edema; <content styleCode="italics">1% to &lt;10% </content>– asthenia, chest pain, chills; <content styleCode="italics">0.1% to &lt;1% – </content>malaise, other superficial edema, peripheral swelling; <content styleCode="italics">&lt;0.1% – </content>gait disturbance.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Skin and Subcutaneous Tissue Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>alopecia, acne, dry skin, hyperhidrosis, urticaria, dermatitis (including eczema); <content styleCode="italics">0.1% to &lt;1% – </content>pigmentation disorder, skin ulcer, bullous conditions, photosensitivity, nail disorder, neutrophilic dermatosis, panniculitis, palmar-plantar erythrodysesthesia syndrome, hair disorder; <content styleCode="italics">&lt;0.1% – </content>leukocytoclastic vasculitis, skin fibrosis.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>lung infiltration, pneumonitis, cough; <content styleCode="italics">0.1% to &lt;1% – </content>asthma, bronchospasm, dysphonia, pulmonary arterial hypertension; <content styleCode="italics">&lt;0.1% </content>– acute respiratory distress syndrome, pulmonary embolism.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Nervous System Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10%– </content>neuropathy (including peripheral neuropathy)<content styleCode="italics">, </content>dizziness, dysgeusia, somnolence; <content styleCode="italics">0.1% to &lt;1% – </content>amnesia, tremor, syncope, balance disorder; <content styleCode="italics">&lt;0.1% </content>– convulsion, cerebrovascular accident, transient ischemic attack, optic neuritis, VIIth nerve paralysis, dementia, ataxia.<content styleCode="bold"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Blood and Lymphatic System Disorders: </content>
                           </content>
                           <content styleCode="italics">0.1% to &lt;1% – </content>lymphadenopathy, lymphopenia; <content styleCode="italics">&lt;0.1% – </content>aplasia pure red cell.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>muscular weakness, musculoskeletal stiffness; <content styleCode="italics">0.1% to &lt;1% – </content>rhabdomyolysis, tendonitis, muscle inflammation, osteonecrosis, arthritis; <content styleCode="italics">&lt;0.1% – </content>epiphyses delayed fusion (reported at <content styleCode="italics">1% to &lt;10% </content>in the pediatric studies), growth retardation (reported at <content styleCode="italics">1% to &lt;10% </content>in the pediatric studies).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Investigations: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>weight increased, weight decreased; <content styleCode="italics">0.1% to &lt;1% – </content>blood creatine phosphokinase increased, gamma-glutamyltransferase increased.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Infections and Infestations: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>pneumonia (including bacterial, viral, and fungal), upper respiratory tract infection/inflammation<content styleCode="italics">, </content>herpes virus infection, enterocolitis infection, sepsis (including fatal outcomes [0.2%]).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism and Nutrition Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>appetite disturbances, hyperuricemia; <content styleCode="italics">0.1% to &lt;1% – </content>hypoalbuminemia, tumor lysis syndrome, dehydration, hypercholesterolemia; <content styleCode="italics">&lt;0.1% – </content>diabetes mellitus.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiac Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>arrhythmia (including tachycardia), palpitations; <content styleCode="italics">0.1% to &lt;1% – </content>angina pectoris, cardiomegaly, pericarditis, ventricular arrhythmia (including ventricular tachycardia), electrocardiogram T-wave abnormal, troponin increased; <content styleCode="italics">&lt;0.1% – </content>cor pulmonale, myocarditis, acute coronary syndrome, cardiac arrest, electrocardiogram PR prolongation, coronary artery disease, pleuropericarditis.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Eye Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>visual disorder (including visual disturbance, vision blurred, and visual acuity reduced), dry eye; <content styleCode="italics">0.1% to &lt;1% </content>– conjunctivitis, visual impairment, lacrimation increased, <content styleCode="italics">&lt;0.1% – </content>photophobia.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Vascular Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>flushing, hypertension; <content styleCode="italics">0.1% to &lt;1% – </content>hypotension, thrombophlebitis, thrombosis; <content styleCode="italics">&lt;0.1% </content>– livedo reticularis, deep vein thrombosis, embolism.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Psychiatric Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% – </content>insomnia, depression; <content styleCode="italics">0.1% to &lt;1% – </content>anxiety, affect lability, confusional state, libido decreased.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pregnancy, Puerperium, and Perinatal Conditions: </content>
                           </content>
                           <content styleCode="italics">&lt;0.1% – </content>abortion.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Reproductive System and Breast Disorders: </content>
                           </content>
                           <content styleCode="italics">0.1% to &lt;1% – </content>gynecomastia, menstrual disorder.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Injury, Poisoning, and Procedural Complications: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% </content>– contusion.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Ear and Labyrinth Disorders: </content>
                           </content>
                           <content styleCode="italics">1% to &lt;10% </content>– tinnitus; <content styleCode="italics">0.1% to &lt;1% </content>– vertigo, hearing loss.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hepatobiliary Disorders: </content>
                           </content>
                           <content styleCode="italics">0.1% to &lt;1% </content>– cholestasis, cholecystitis, hepatitis.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Renal and Urinary Disorders: </content>
                           </content>
                           <content styleCode="italics">0.1% to &lt;1% </content>– urinary frequency, renal failure, proteinuria; <content styleCode="italics">&lt;0.1% – </content>renal impairment.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Immune System Disorders: </content>
                           </content>
                           <content styleCode="italics">0.1% to &lt;1% </content>– hypersensitivity (including erythema nodosum).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Endocrine Disorders: </content>
                           </content>
                           <content styleCode="italics">0.1% to &lt;1% – </content>hypothyroidism; <content styleCode="italics">&lt;0.1% – </content>hyperthyroidism, thyroiditis.<br/>
                           <content styleCode="italics">
                              <br/> Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.3">
                     <id root="6a5ca456-0c75-4ce5-a31a-b83bf891e8c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following additional adverse reactions have been identified during post approval use of dasatinib. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Infections: </content>hepatitis B virus reactivation</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Cardiac disorders: </content>atrial fibrillation/atrial flutter</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Respiratory, thoracic, and mediastinal disorders: </content>interstitial lung disease, chylothorax</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Skin and subcutaneous tissue disorders: </content>Stevens-Johnson syndrome</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Renal and urinary disorders: </content>nephrotic syndrome</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Blood and lymphatic system disorders: </content>thrombotic microangiopathy<br/>
                           <br/>
                           <content styleCode="bold">Hepatobiliary disorders: </content>hepatotoxicity</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="acc9c4e4-5450-43a1-ac50-85c640a5dd67"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240803"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Strong CYP3A4 Inhibitors:</content> Dose reduction may be necessary. (<linkHtml href="#Section_2.2">2.3</linkHtml>, <linkHtml href="#Section_7.1">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Strong CYP3A4 Inducers:</content> Dose increase may be necessary. (<linkHtml href="#Section_2.2">2.3</linkHtml>, <linkHtml href="#Section_7.1">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Antacids:</content> Avoid simultaneous administration. (<linkHtml href="#Section_7.1">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">H<sub>2</sub> Antagonists and Proton Pump Inhibitors:</content> Avoid coadministration. (<linkHtml href="#Section_7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="ca443d46-7162-4da9-9f2d-861f0d1ca7db"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.1 Effect of Other Drugs on Dasatinib</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Strong CYP3A4 Inhibitors</content>
                        </paragraph>
                        <br/>
                        <paragraph>The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations <content styleCode="italics">[see <linkHtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Increased dasatinib concentrations may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors. If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a dasatinib dose reduction <content styleCode="italics">[see <linkHtml href="#Section_2.4">Dosage and Administration (2.5)</linkHtml>]</content>.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Strong CYP3A4 Inducers</content>
                        </paragraph>
                        <paragraph>The coadministration of dasatinib with strong CYP3A inducers may decrease dasatinib concentrations <content styleCode="italics">[see <linkHtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkHtml>]. </content>Decreased dasatinib concentrations may reduce efficacy. Consider alternative drugs with less enzyme induction potential. If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dasatinib dose increase.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Gastric Acid Reducing Agents</content>
                        </paragraph>
                        <paragraph>The coadministration of dasatinib with a gastric acid reducing agent may decrease the concentrations of dasatinib. Decreased dasatinib concentrations may reduce efficacy.</paragraph>
                        <br/>
                        <paragraph>Do not administer H<sub>2</sub> antagonists or proton pump inhibitors with dasatinib. Consider the use of antacids in place of H<sub>2</sub> antagonists or proton pump inhibitors. Administer the antacid at least 2 hours prior to or 2 hours after the dose of dasatinib. Avoid simultaneous administration of dasatinib with antacids.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="692c192b-1259-4369-aa6e-120347b5fdde"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240803"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Lactation: </content>Advise women not to breastfeed. (<linkHtml href="#Section_8.2">8.2</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="9cc19796-98d4-4770-bafb-43578d5dbaa9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <br/>
                        <paragraph>Based on limited human data, dasatinib can cause fetal harm when administered to a pregnant woman. Adverse pharmacologic effects including hydrops fetalis, fetal leukopenia, and fetal thrombocytopenia have been reported with maternal exposure to dasatinib. Animal reproduction studies in rats have demonstrated extensive mortality during organogenesis, the fetal period, and in neonates. Skeletal malformations were observed in a limited number of surviving rat and rabbit conceptuses. These findings occurred at dasatinib plasma concentrations below those in humans receiving therapeutic doses of dasatinib <content styleCode="italics">[see Data]</content>. Advise a pregnant woman of the potential risk to a fetus.</paragraph>
                        <br/>
                        <paragraph>The estimated background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Transplacental transfer of dasatinib has been reported. Dasatinib has been measured in fetal plasma and amniotic fluid at concentrations comparable to those in maternal plasma. Hydrops fetalis, fetal leukopenia, and fetal thrombocytopenia have been reported with maternal exposure to dasatinib. These adverse pharmacologic effects on the fetus are similar to adverse reactions observed in adult patients and may result in fetal harm or neonatal death <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#Section_5.3">5.3)</linkHtml>]</content>.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Based on human experience, dasatinib is suspected to cause congenital malformations, including neural tube defects, and harmful pharmacological effects on the fetus when administered during pregnancy.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In nonclinical studies at plasma concentrations below those observed in humans receiving therapeutic doses of dasatinib, embryo-fetal toxicities were observed in rats and rabbits. Fetal death was observed in rats. In both rats and rabbits, the lowest doses of dasatinib tested (rat: 2.5 mg/kg/day [15 mg/m<sup>2</sup>/day] and rabbit: 0.5 mg/kg/day [6 mg/m<sup>2</sup>/day]) resulted in embryo-fetal toxicities. These doses produced maternal AUCs of 105 ng•h/mL and 44 ng•h/mL (0.1-fold the human AUC) in rats and rabbits, respectively. Embryo-fetal toxicities included skeletal malformations at multiple sites (scapula, humerus, femur, radius, ribs, and clavicle), reduced ossification (sternum; thoracic, lumbar, and sacral vertebrae; forepaw phalanges; pelvis; and hyoid body), edema, and microhepatia. In a pre- and postnatal development study in rats, administration of dasatinib from gestation day (GD) 16 through lactation day (LD) 20, GD 21 through LD 20, or LD 4 through LD 20 resulted in extensive pup mortality at maternal exposures that were below the exposures in patients treated with dasatinib at the recommended labeling dose.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="6d893d99-9628-40ef-a8f6-0fadf2a12df6"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <br/>
                        <paragraph>No data are available regarding the presence of dasatinib in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. However, dasatinib is present in the milk of lactating rats. Because of the potential for serious adverse reactions in nursing children from dasatinib, breastfeeding is not recommended during treatment with dasatinib and for 2 weeks after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="6fa44e0a-4b58-44c9-9920-4f30c47fdf3e"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Dasatinib can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#Section_8.1">Use in Specific Populations (8.1)</linkHtml>]</content>. </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with dasatinib and for 30 days after the last dose.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <br/>
                        <paragraph>Based on animal data, dasatinib may result in damage to female and male reproductive tissues <content styleCode="italics">[see <linkHtml href="#Section_13.1">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="aa192103-59a8-4335-9728-4ac51f68f54b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Monitor bone growth and development in pediatric patients <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#Section_5.10">Warnings and Precautions (5.10)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib)</content>
                           <content styleCode="italics"> tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.<content styleCode="bold"/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="f48863cb-4932-436b-b6e0-88774f0bb792"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 2712 patients in clinical studies of dasatinib, 617 (23%) were 65 years of age and older, and 123 (5%) were 75 years of age and older. No differences in confirmed Complete Cytogenetic Response (cCCyR) and MMR were observed between older and younger patients. While the safety profile of dasatinib in the geriatric population was similar to that in the younger population, patients aged 65 years and older are more likely to experience the commonly reported adverse reactions of fatigue, pleural effusion, diarrhea, dyspnea, cough, lower gastrointestinal hemorrhage, and appetite disturbance, and more likely to experience the less frequently reported adverse reactions of abdominal distention, dizziness, pericardial effusion, congestive heart failure, hypertension, pulmonary edema, and weight decrease, and should be monitored closely.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="71fb97d1-c6bb-4f46-9fbc-b461654c3c38"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Experience with overdose of dasatinib in clinical studies is limited to isolated cases. The highest overdosage of 280 mg per day for 1 week was reported in two patients and both developed severe myelosuppression and bleeding. Since dasatinib is associated with severe myelosuppression <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#Section_6.1">Adverse Reactions (6.1)</linkHtml>]</content>, monitor patients who ingest more than the recommended dosage closely for myelosuppression and give appropriate supportive treatment.</paragraph>
                  <br/>
                  <paragraph>Acute overdose in animals was associated with cardiotoxicity. Evidence of cardiotoxicity included ventricular necrosis and valvular/ventricular/atrial hemorrhage at single doses ≥100 mg/kg (600 mg/m<sup>2</sup>) in rodents. There was a tendency for increased systolic and diastolic blood pressure in monkeys at single doses ≥10 mg/kg (120 mg/m<sup>2</sup>).</paragraph>
               </text>
               <effectiveTime value="20240803"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="f7d6fb84-1d82-4312-ae53-5f25188a5c37"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <br/>
                  <paragraph>Dasatinib is a kinase inhibitor. The chemical name for dasatinib is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thaizolecarboxamide, monohydrate. The molecular formula is C<sub>22</sub>H<sub>26</sub>ClN<sub>7</sub>O<sub>2</sub>S. H<sub>2</sub>O, which corresponds to a formula weight of 506.02 (monohydrate). Dasatinib has the following chemical structure:</paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Dasatinib is a white to off-white powder. The drug substance is sparingly soluble in dimethyl sulphoxide, N, N dimethyl formamide and practically insoluble in water.<br/>
                     <br/>Dasatinib tablets are white to off-white, biconvex, film-coated tablets containing dasatinib, with the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The tablet coating consists of hypromellose, titanium dioxide and polyethylene glycol.</paragraph>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>chemical-structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-str.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="e4112f8d-ee32-4605-8eed-5189b90165e2"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240803"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="40c100bc-4e61-4b95-beda-acc3c35ca148"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib could overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="4c2e02e5-a5df-44e1-ae43-9d53d299c052"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>Of 2440 patients treated with dasatinib at all doses tested in clinical trials, 16 patients (&lt;1%) had QTc prolongation reported as an adverse reaction. Twenty-two patients (1%) experienced a QTcF &gt; 500 ms. In 865 patients with leukemia treated with dasatinib 70 mg BID in five Phase 2 studies, the maximum mean changes in QTcF (90% upper bound CI) from baseline ranged from 7 ms to 13.4 ms.</paragraph>
                        <br/>
                        <paragraph>An analysis of the data from five Phase 2 studies in patients (70 mg BID) and a Phase 1 study in healthy subjects (100 mg single dose) suggests that there is a maximum increase of 3 to 6 milliseconds in Fridericia corrected QTc interval from baseline for subjects receiving therapeutic doses of dasatinib, with associated upper 95% confidence intervals &lt;10 msec.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="f80aff28-2ac5-4a81-8db9-453b29b692c3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of dasatinib exhibits dose proportional increases in AUC and linear elimination characteristics over the dose range of 15 mg/day (0.15 times the lowest approved recommended dose) to 240 mg/day (1.7 times the highest approved recommended dose).</paragraph>
                        <br/>
                        <paragraph>At 100 mg QD, the maximum concentration at steady state (C<sub>max</sub>) is 82.2 ng/mL (CV% 69%), area under the plasma drug concentration time curve (AUC) is 397 ng/mL*hr (CV% 55%). The clearance of dasatinib is found to be time-invariant. When administered to adult healthy subjects as dispersed tablets in juice, the adjusted geometric mean ratio was 0.97 (90% CI: 0.85, 1.10) for C<sub>max </sub>and 0.84 (90% CI: 0.78, 0.91) for AUC as compared to intact tablets.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Absorption</content>
                        </paragraph>
                        <paragraph>The maximum plasma concentrations (C<sub>max</sub>) of dasatinib are observed between 0.5 hours and 6 hours (T<sub>max</sub>) following oral administration.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Food Effect</content>
                           </content>
                        </paragraph>
                        <paragraph>A high-fat meal increased the mean AUC of dasatinib following a single dose of 100 mg by 14%. The total calorie content of the high-fat meal was 985 kcal. The calories derived from fat, carbohydrates, and protein were 52%, 34%, and 14% for the high-fat meal.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Distribution</content>
                        </paragraph>
                        <paragraph>The apparent volume of distribution is 2505 L (CV% 93%).</paragraph>
                        <br/>
                        <paragraph>Binding of dasatinib to human plasma proteins <content styleCode="italics">in vitro </content>was approximately 96% and of its active metabolite was 93%, with no concentration dependence over the range of 100 ng/mL to 500 ng/mL.</paragraph>
                        <br/>
                        <paragraph>Dasatinib is a P-gp substrate <content styleCode="italics">in vitro</content>.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Elimination</content>
                        </paragraph>
                        <paragraph>The mean terminal half-life of dasatinib is 3 hours to 5 hours. The mean apparent oral clearance is 363.8 L/hr (CV% 81.3%).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>Dasatinib is metabolized in humans, primarily by CYP3A4. CYP3A4 is the primary enzyme responsible for the formation of the active metabolite. Flavin-containing monooxygenase 3 (FMO-3) and uridine diphosphate-glucuronosyltransferase (UGT) enzymes are also involved in the formation of dasatinib metabolites.</paragraph>
                        <br/>
                        <paragraph>The exposure of the active metabolite, which is equipotent to dasatinib, represents approximately 5% of the AUC of dasatinib. The active metabolite of dasatinib is unlikely to play a major role in the observed pharmacology of the drug. Dasatinib also has several other inactive oxidative metabolites.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Excretion</content>
                           </content>
                        </paragraph>
                        <paragraph>Elimination is primarily via the feces. Following a single radiolabeled dose of oral dasatinib, 4% of the administered radioactivity was recovered in the urine and 85% in the feces within 10 days. Unchanged dasatinib accounted for 0.1% of the administered dose in the urine and 19% of the administered dose in the feces with the remainder of the dose being metabolites.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Specific Populations</content>
                        </paragraph>
                        <paragraph>Age, sex, and renal impairment (creatinine clearance 21.6 mL/min to 342.3 mL/min as estimated by Cockcroft Gault) have no clinically relevant effect on the pharmacokinetics of dasatinib.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Patients with Hepatic Impairment</content>
                           </content>
                        </paragraph>
                        <paragraph>Compared to subjects with normal liver function, patients with moderate hepatic impairment (Child Pugh B) had decreases in mean C<sub>max</sub> by 47% and mean AUC by 8%. Patients with severe hepatic impairment (Child Pugh C) had decreases in mean C<sub>max</sub> by 43% and in mean AUC by 28% compared to the subjects with normal liver function.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Cytochrome P450 Enzymes</content>
                           </content>
                        </paragraph>
                        <paragraph>The coadministration of ketoconazole (strong CYP3A4 inhibitor) twice daily increased the mean C<sub>max</sub> of dasatinib by 4-fold and the mean AUC of dasatinib by 5-fold following a single oral dose of 20 mg.</paragraph>
                        <br/>
                        <paragraph>The coadministration of rifampin (strong CYP3A4 inducer) once daily decreased the mean C<sub>max</sub> of dasatinib by 81% and the mean AUC of dasatinib by 82%.</paragraph>
                        <br/>
                        <paragraph>Dasatinib is a time-dependent inhibitor of CYP3A4. Dasatinib does not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 2E1. Dasatinib does not induce CYP enzymes.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Gastric Acid Reducing Agents</content>
                           </content>
                        </paragraph>
                        <paragraph>The administration of 30 mL of aluminum hydroxide/magnesium hydroxide 2 hours prior to a single dose of dasatinib was associated with no relevant change in the mean AUC of dasatinib; however, the mean C<sub>max</sub> of dasatinib was increased by 26%. </paragraph>
                        <br/>
                        <paragraph>The simultaneous administration of 30 mL of aluminum hydroxide/magnesium hydroxide with a single dose of dasatinib was associated with a 55% reduction in the mean AUC of dasatinib and a 58% reduction in the mean C<sub>max</sub> of dasatinib.</paragraph>
                        <br/>
                        <paragraph>The administration of a single dose of dasatinib 10 hours following famotidine (H<sub>2</sub> antagonist) reduced the mean AUC of dasatinib by 61% and the mean C<sub>max</sub> of dasatinib by 63%.</paragraph>
                        <br/>
                        <paragraph>The administration of a single 100 mg dose of dasatinib 22 hours following a 40 mg dose of omeprazole (proton pump inhibitor) at steady state reduced the mean AUC of dasatinib by 43% and the mean C<sub>max</sub> of dasatinib by 42%.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Transporters</content>
                           </content>
                        </paragraph>
                        <paragraph>Dasatinib is not an inhibitor of P-gp <content styleCode="italics">in vitro</content>.<br/>
                           <content styleCode="italics">
                              <br/> Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="4609d5fc-397c-4e3b-9e6d-3a4e2c4e872b"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240803"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="1d8fbb48-5cf4-48d0-a947-64b875028a4d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>In a 2-year carcinogenicity study, rats were administered oral doses of dasatinib at 0.3, 1, and 3 mg/kg/day. The highest dose resulted in a plasma drug exposure (AUC) level approximately 60% of the human exposure at 100 mg once daily. Dasatinib induced a statistically significant increase in the combined incidence of squamous cell carcinomas and papillomas in the uterus and cervix of high-dose females and prostate adenoma in low-dose males.</paragraph>
                        <br/>
                        <paragraph>Dasatinib was clastogenic when tested <content styleCode="italics">in vitro </content>in Chinese hamster ovary cells, with and without metabolic activation. Dasatinib was not mutagenic when tested in an <content styleCode="italics">in vitro </content>bacterial cell assay (Ames test) and was not genotoxic in an <content styleCode="italics">in vivo </content>rat micronucleus study.</paragraph>
                        <br/>
                        <paragraph>Dasatinib did not affect mating or fertility in male and female rats at plasma drug exposure (AUC) similar to the human exposure at 100 mg daily. In repeat dose studies, administration of dasatinib resulted in reduced size and secretion of seminal vesicles, and immature prostate, seminal vesicle, and testis. The administration of dasatinib resulted in uterine inflammation and mineralization in monkeys, and cystic ovaries and ovarian hypertrophy in rodents.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="316d7776-7531-4d24-b24d-da51241565f8"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20240803"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="cea21c40-dc72-425b-b1ff-210f52252f79"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.1 Newly Diagnosed Chronic Phase CML in Adults</title>
                     <text>
                        <paragraph>DASISION (Dasatinib vs Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients) (NCT00481247) was an open-label, multicenter, international, randomized trial conducted in adult patients with newly diagnosed chronic phase CML. A total of 519 patients were randomized to receive either dasatinib 100 mg once daily or imatinib 400 mg once daily. Patients with a history of cardiac disease were included in this trial except those who had a myocardial infarction within 6 months, congestive heart failure within 3 months, significant arrhythmias, or QTc prolongation. The primary endpoint was the rate of confirmed complete cytogenetic response (CCyR) within 12 months. Confirmed CCyR was defined as a CCyR noted on two consecutive occasions (at least 28 days apart). </paragraph>
                        <br/>
                        <paragraph>Median age was 46 years in the dasatinib group and 49 years in the imatinib groups, with 10% and 11% of patients ≥65 years of age, respectively. There were slightly more male than female patients in both groups (59% vs 41%). Fifty-three percent of all patients were Caucasian and 39% were Asian. At baseline, the distribution of Hasford scores was similar in the dasatinib and imatinib treatment groups (low risk: 33% and 34%; intermediate risk: 48% and 47%; high risk: 19% and 19%, respectively). With a minimum of 12 months follow-up, 85% of patients randomized to dasatinib and 81% of patients randomized to imatinib were still on study. </paragraph>
                        <br/>
                        <paragraph>With a minimum of 24 months follow-up, 77% of patients randomized to dasatinib and 75% of patients randomized to imatinib were still on study and with a minimum of 60 months follow-up, 61% and 62% of patients, respectively, were still on treatment at the time of study closure. </paragraph>
                        <br/>
                        <paragraph>Efficacy results are summarized in Table 16.<br/>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 16: Efficacy Results in a Randomized Newly Diagnosed Chronic Phase CML Trial 
			</caption>
                           <colgroup>
                              <col width="39.3%"/>
                              <col width="11.44%"/>
                              <col width="24.48%"/>
                              <col width="24.76%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="justify">
                                    <sup>a</sup>  Confirmed CCyR is defined as a CCyR noted on two consecutive occasions at least 28 days apart.<br/>
                                    <sup>b</sup> Major molecular response (at any time) was defined as BCR-ABL ratios ≤0.1% by RQ-PCR in peripheral    blood samples standardized on the International scale. These are cumulative rates representing minimum follow up for the time frame specified.<br/>*  Adjusted for Hasford score and indicated statistical significance at a pre-defined nominal level of significance.<br/>CI = confidence interval.<br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Dasatinib</content>
                                    <br/>
                                    <content styleCode="bold">(n=259)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Imatinib</content>
                                    <br/>
                                    <content styleCode="bold">(n=260)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Confirmed CCyR<sup>a</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">      Within 12 months    (95% CI)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">76.8% (71.2 to 81.8)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">66.2% (60.1 to 71.9)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">      P-value</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0.007*<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Major Molecular Response<sup>b</sup>
                                    </content>
                                    <content styleCode="bold"/>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">     12 months (95% CI)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">52.1% (45.9 to 58.3)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">33.8% (28.1 to 39.9)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">     P-value</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">&lt;0.0001<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">     60 months (95% CI)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">76.4% (70.8 to 81.5)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">64.2% (58.1 to 70.1)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The confirmed CCyR within 24, 36, and 60 months for dasatinib versus imatinib arms were 80% versus 74%, 83% versus 77%, and 83% versus 79%, respectively. The MMR at 24 and 36 months for dasatinib versus imatinib arms were 65% versus 50% and 69% versus 56%, respectively.</paragraph>
                        <br/>
                        <paragraph>After 60 months follow-up, median time to confirmed CCyR was 3.1 months in 215 dasatinib responders and 5.8 months in 204 imatinib responders. Median time to MMR after 60 months follow-up was 9.3 months in 198 dasatinib responders and 15.0 months in 167 imatinib responders.</paragraph>
                        <br/>
                        <paragraph>At 60 months, 8 patients (3%) on the dasatinib arm progressed to either accelerated phase or blast crisis while 15 patients (6%) on the imatinib arm progressed to either accelerated phase or blast crisis.</paragraph>
                        <br/>
                        <paragraph>The estimated 60-month survival rates for dasatinib- and imatinib-treated patients were 90.9% (CI: 86.6% to 93.8%) and 89.6% (CI: 85.2% to 92.8%), respectively. Based on data 5 years after the last patient was enrolled in the trial, 83% and 77% of patients were known to be alive in the dasatinib and imatinib treatment groups, respectively, 10% were known to have died in both treatment groups, and 7% and 13% had unknown survival status in the dasatinib and imatinib treatment groups, respectively.</paragraph>
                        <br/>
                        <paragraph>At 60 months follow-up in the dasatinib arm, the rate of MMR at any time in each risk group determined by Hasford score was 90% (low risk), 71% (intermediate risk) and 67% (high risk). In the imatinib arm, the rate of MMR at any time in each risk group determined by Hasford score was 69% (low risk), 65% (intermediate risk), and 54% (high risk).</paragraph>
                        <br/>
                        <paragraph>BCR-ABL sequencing was performed on blood samples from patients in the newly diagnosed trial who discontinued dasatinib or imatinib therapy. Among dasatinib-treated patients the mutations detected were T315I, F317I/L, and V299L.</paragraph>
                        <br/>
                        <paragraph>Dasatinib does not appear to be active against the T315I mutation, based on <content styleCode="italics">in vitro </content>data.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="7532b931-e6e9-4d81-9db9-69e61e74493f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.2 Imatinib-Resistant or -Intolerant CML or Ph+ ALL in Adults</title>
                     <text>
                        <paragraph>The efficacy and safety of dasatinib were investigated in adult patients with CML or Ph+ ALL whose disease was resistant to or who were intolerant to imatinib: 1158 patients had chronic phase CML, 858 patients had accelerated phase, myeloid blast phase, or lymphoid blast phase CML, and 130 patients had Ph+ ALL. In a clinical trial in chronic phase CML, resistance to imatinib was defined as failure to achieve a complete hematologic response (CHR; after 3 months), major cytogenetic response (MCyR; after 6 months), or complete cytogenetic response (CCyR; after 12 months); or loss of a previous molecular response (with concurrent ≥10% increase in Ph+ metaphases), cytogenetic response, or hematologic response. Imatinib intolerance was defined as inability to tolerate 400 mg or more of imatinib per day or discontinuation of imatinib because of toxicity.</paragraph>
                        <br/>
                        <paragraph>Results described below are based on a minimum of 2 years follow-up after the start of dasatinib therapy in patients with a median time from initial diagnosis of approximately 5 years. Across all studies, 48% of patients were women, 81% were white, 15% were black or Asian, 25% were 65 years of age or older, and 5% were 75 years of age or older. Most patients had long disease histories with extensive prior treatment, including imatinib, cytotoxic chemotherapy, interferon, and stem cell transplant. Overall, 80% of patients had imatinib-resistant disease and 20% of patients were intolerant to imatinib. The maximum imatinib dose had been 400 to 600 mg/day in about 60% of the patients and &gt;600 mg/day in 40% of the patients.</paragraph>
                        <br/>
                        <paragraph>The primary efficacy endpoint in chronic phase CML was MCyR, defined as elimination (CCyR) or substantial diminution (by at least 65%, partial cytogenetic response) of Ph+ hematopoietic cells. The primary efficacy endpoint in accelerated phase, myeloid blast phase, lymphoid blast phase CML, and Ph+ ALL was major hematologic response (MaHR), defined as either a CHR or no evidence of leukemia (NEL).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Chronic Phase CML</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Dose-Optimization Trial: </content>A randomized, open-label trial (NCT00123474) was conducted in adult patients with chronic phase CML to evaluate the efficacy and safety of dasatinib administered once daily compared with dasatinib administered twice daily. Patients with significant cardiac diseases, including myocardial infarction within 6 months, congestive heart failure within 3 months, significant arrhythmias, or QTc prolongation were excluded from the trial. The primary efficacy endpoint was MCyR in patients with imatinib-resistant CML. A total of 670 patients, of whom 497 had imatinib-resistant disease, were randomized to the dasatinib 100 mg once-daily, 140 mg once-daily, 50 mg twice-daily, or 70 mg twice-daily group. Median duration of treatment was 22 months.</paragraph>
                        <br/>
                        <paragraph>Efficacy was achieved across all dasatinib treatment groups with the once-daily schedule demonstrating comparable efficacy (non-inferiority) to the twice-daily schedule on the primary efficacy endpoint (difference in MCyR 1.9%; 95% CI [−6.8% to 10.6%]); however, the 100 mg once-daily regimen demonstrated improved safety and tolerability.</paragraph>
                        <br/>
                        <paragraph>Efficacy results are presented in Tables 17 and 18 for adult patients with chronic phase CML who received the recommended starting dose of 100 mg once daily.<br/>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 17:  Efficacy of Dasatinib in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Phase CML (minimum of 24 months follow-up) 
			</caption>
                           <colgroup>
                              <col width="50%"/>
                              <col width="50%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="2" align="justify">
                                    <sup>a </sup> CHR (response confirmed after 4 weeks): WBC ≤ institutional ULN, platelets &lt;450,000/mm<sup>3</sup>, no blasts or  promyelocytes in peripheral blood, &lt;5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt;20%, and no extramedullary involvement.<br/>
                                    <sup>b</sup>  MCyR combines both complete (0% Ph+ metaphases) and partial (&gt;0% to 35%) responses.<br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">All Patients</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">100 mg Once Daily </content>
                                    <br/>
                                    <content styleCode="bold">(n=167)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Hematologic Response Rate % (95% CI)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">    CHR<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">92% (86 to 95)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Cytogenetic Response Rate % (95% CI)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">    MCyR<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">63% (56 to 71)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">    CCyR<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">50% (42 to 58)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 18: Long-Term MMR of Dasatinib in the Dose Optimization Trial: Adult Patients with Imatinib-Resistant or -Intolerant Chronic Phase CML<sup>a</sup>
                           </caption>
                           <colgroup>
                              <col width="36.28%"/>
                              <col width="19.82%"/>
                              <col width="25.96%"/>
                              <col width="17.94%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="justify">
                                    <sup>a   </sup> Results reported in recommended starting dose of 100 mg once daily.<br/>
                                    <sup>b    </sup>Major molecular response criteria: Defined as BCR-ABL/control transcripts ≤0.1% by RQ-PCR in peripheral blood samples. <br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" valign="top"> <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="3" align="center" valign="middle">
                                    <content styleCode="bold">Minimum Follow-up Period</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">2 Years</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">5 Years</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">7 Years</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Major Molecular Response<sup>b </sup>% (n/N)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   All Patients Randomized<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">34% (57/167)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">43% (71/167)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">44% (73/167)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Imatinib-Resistant Patients<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">33% (41/124)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">40% (50/124)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">41% (51/124)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">   Imatinib-Intolerant Patients<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">37% (16/43)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">49% (21/43)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">51% (22/43)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Based on data 7 years after the last patient was enrolled in the trial, 44% were known to be alive, 31% were known to have died, and 25% had an unknown survival status. </paragraph>
                        <br/>
                        <paragraph>By 7 years, transformation to either accelerated or blast phase occurred in nine patients on treatment in the 100 mg once-daily treatment group.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Advanced Phase CML and Ph+ ALL</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Dose-Optimization Trial: </content>One randomized open-label trial (NCT00123487) was conducted in patients with advanced phase CML (accelerated phase CML, myeloid blast phase CML, or lymphoid blast phase CML) to evaluate the efficacy and safety of dasatinib administered once daily compared with dasatinib administered twice daily. The primary efficacy endpoint was MaHR. A total of 611 patients were randomized to either the dasatinib 140 mg once-daily or 70 mg twice-daily group. Median duration of treatment was approximately 6 months for both treatment groups. The once-daily schedule demonstrated comparable efficacy (non-inferiority) to the twice-daily schedule on the primary efficacy endpoint; however, the 140-mg once-daily regimen demonstrated improved safety and tolerability. </paragraph>
                        <br/>
                        <paragraph>Response rates for patients in the 140 mg once-daily group are presented in Table 19.</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 19: Efficacy of Dasatinib in Imatinib-Resistant or –Intolerant Advanced Phase CML and Ph+ ALL (2-Year Results) 
			</caption>
                           <colgroup>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="justify">
                                    <sup>a</sup>    Hematologic response criteria (all responses confirmed after 4 weeks): Major hematologic response: (MaHR) = complete hematologic response (CHR) + no evidence of leukemia (NEL).<br/>CHR: WBC ≤ institutional ULN, ANC ≥1000/mm<sup>3</sup>, platelets ≥100,000/mm<sup>3</sup>, no blasts or promyelocytes in peripheral blood, bone marrow blasts ≤5%, &lt;5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt;20%, and no extramedullary involvement.<br/>NEL: same criteria as for CHR but ANC ≥500/mm<sup>3</sup> and &lt;1000/mm<sup>3</sup>, or platelets ≥20,000/mm<sup>3</sup> and ≤100,000/mm<sup>3</sup>.<br/>
                                    <sup>b      </sup>MCyR combines both complete (0% Ph+ metaphases) and partial (&gt;0% to 35%) responses.<br/>CI = confidence interval ULN = upper limit of normal range.<br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="top"> <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="4" align="center" valign="middle">
                                    <content styleCode="bold">140 mg Once Daily</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="top"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Accelerated</content>
                                    <br/>
                                    <content styleCode="bold">(n=158)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Myeloid Blast</content>
                                    <br/>
                                    <content styleCode="bold">(n=75)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Lymphoid Blast</content>
                                    <br/>
                                    <content styleCode="bold">(n=33)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Ph+ ALL</content>
                                    <br/>
                                    <content styleCode="bold">(n=40)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">MaHR<sup>a</sup>
                                    </content>
                                    <br/>      (95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">66%<br/>(59 to 74)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">28%<br/>(18 to 40)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">42%<br/>(26 to 61)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">38%<br/>(23 to 54)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">CHR<sup>a</sup>
                                    <br/>      (95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">47%<br/>(40 to 56)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">17%<br/>(10 to 28)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21%<br/>(9 to 39)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">33%<br/>(19 to 49)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">NEL<sup>a</sup>
                                    <br/>     (95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">19%<br/>(13 to 26)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11%<br/>(5 to 20)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21%<br/>(9 to 39)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5%<br/>(1 to 17)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">MCyR</content>
                                    <sup>b</sup>
                                    <br/>     (95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">39%<br/>(31 to 47)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">28%<br/>(18 to 40)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">52%<br/>(34 to 69)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">70%<br/>(54 to 83)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">CCyR<br/>     (95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">32%<br/>(25 to 40)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">17%<br/>(10 to 28)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">39%<br/>(23 to 58)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">50%<br/>(34 to 66)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In the dasatinib 140 mg once-daily group, the median time to MaHR was 1.9 months (min- max: 0.7 to 14.5) for patients with accelerated phase CML, 1.9 months (min-max: 0.9 to 6.2) for patients with myeloid blast phase CML, and 1.8 months (min-max: 0.9 to 2.8) for patients with lymphoid blast phase CML. </paragraph>
                        <br/>
                        <paragraph>In patients with myeloid blast phase CML, the median duration of MaHR was 8.1 months (min-max: 2.7 to 21.1) and 9.0 (min-max: 1.8 to 23.1) months for the 140 mg once-daily group and the 70 mg twice-daily group, respectively. In patients with lymphoid blast phase CML, the median duration of MaHR was 4.7 months (min-max: 3.0 to 9.0) and 7.9 months (min-max: 1.6 to 22.1) for the 140 mg once-daily group and the 70 mg twice-daily group, respectively. In patients with Ph+ ALL who were treated with dasatinib 140 mg once-daily, the median duration of MaHR was 4.6 months (min-max: 1.4 to 10.2). The medians of progression-free survival for patients with Ph+ ALL treated with dasatinib 140 mg once-daily and 70 mg twice-daily were 4.0 months (min-max: 0.4 to 11.1) and 3.1 months (min-max: 0.3 to 20.8), respectively.<br/>
                           <content styleCode="italics">
                              <br/> Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_15">
               <id root="3f6f0a26-bc47-478c-80b0-bd0ce3221986"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1.   http://www.osha.gov/SLTC/hazardousdrugs/index.html</paragraph>
               </text>
               <effectiveTime value="20240803"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="7ee5ae91-73ce-45b6-a385-bb4ca2e013fa"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20240803"/>
               <component>
                  <section ID="Section_17.1">
                     <id root="8040b1fa-b93c-4443-b095-c6a02b2a194e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Dasatinib Tablets, 20 mg</content> are white to off-white, biconvex, round, film-coated tablet with “D” debossed on one side and “20” on the other side and are supplied as follows:</paragraph>
                        <br/>
                        <paragraph>                       Bottles of 60                                                NDC 59651-542-60</paragraph>
                        <paragraph>                       Cartons of 15 (1 x 15) Unit-dose Tablets    NDC 59651-542-15   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Dasatinib Tablets, 50 mg</content> are white to off-white, biconvex, oval, film-coated tablet with “D” debossed on one side and “50” on the other side and are supplied as follows:</paragraph>
                        <br/>
                        <paragraph>                       Bottles of 60                                                NDC 59651-543-60</paragraph>
                        <paragraph>                       Cartons of 15 (1 x 15) Unit-dose Tablets    NDC 59651-543-15   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Dasatinib Tablets, 70 mg</content> are white to off-white, biconvex, round, film-coated tablet with “D” debossed on one side and “70” on the other side and are supplied as follows:</paragraph>
                        <br/>
                        <paragraph>                       Bottles of 60                                                NDC 59651-544-60 </paragraph>
                        <paragraph>                       Cartons of 15 (1 x 15) Unit-dose Tablets    NDC 59651-544-15 </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Dasatinib Tablets, 80 mg</content> are white to off-white, biconvex, triangle, film-coated tablet with “D” debossed on one side and “80” on the other side and are supplied as follows:</paragraph>
                        <br/>
                        <paragraph>                       Bottles of 30                                                 NDC 59651-545-30</paragraph>
                        <paragraph>                       Cartons of 15 (1 x 15) Unit-dose Tablets     NDC 59651-545-15<content styleCode="underline">   </content>
                           <content styleCode="underline"> </content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Dasatinib Tablets, 100 mg</content> are white to off-white, biconvex, oval, film-coated tablet with “D” debossed on one side and “100” on the other side and are supplied as follows:</paragraph>
                        <br/>
                        <paragraph>                       Bottles of 30                                                 NDC 59651-546-30</paragraph>
                        <paragraph>                       Cartons of 15 (1 x 15) Unit-dose Tablets     NDC 59651-546-15   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Dasatinib Tablets, 140 mg</content> are white to off-white, biconvex, round, film-coated tablet with “D” debossed on one side and “140” on the other side and are supplied as follows:</paragraph>
                        <br/>
                        <paragraph>                       Bottles of 30                                                 NDC 59651-547-30</paragraph>
                        <paragraph>                       Cartons of 15 (1 x 15) Unit-dose Tablets     NDC 59651-547-15   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Storage</content>
                        </paragraph>
                        <paragraph>Dasatinib tablets should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Handling and Disposal</content>
                        </paragraph>
                        <paragraph>Dasatinib is an antineoplastic product. Follow special handling and disposal procedures.<sup>1 </sup>
                        </paragraph>
                        <br/>
                        <paragraph>Personnel who are pregnant should avoid exposure to crushed or broken tablets.</paragraph>
                        <br/>
                        <paragraph>Dasatinib tablets consist of a core tablet, surrounded by a film coating to prevent exposure of healthcare professionals to the active substance. The use of latex or nitrile gloves for appropriate disposal when handling tablets that are inadvertently crushed or broken is recommended, to minimize the risk of dermal exposure.</paragraph>
                     </text>
                     <effectiveTime value="20240803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="305f5271-7cf2-48b1-9626-9894d582fb30"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#Unclassified_Section_24">Patient Information</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Myelosuppression<br/>
                     </content>
                     <br/> Inform patients of the possibility of developing low blood cell counts. Advise patients to immediately report fever particularly in association with any suggestion of infection <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1)</linkHtml>].</content> <br/>
                     <content styleCode="bold">
                        <br/> Bleeding<br/>
                     </content>
                     <br/> Inform patients of the possibility of serious bleeding and to report immediately any signs or symptoms suggestive of hemorrhage (unusual bleeding or easy bruising) <content styleCode="italics">[see </content>
                     <content styleCode="italics">
                        <linkHtml href="#Section_5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.<br/>
                     <content styleCode="bold">
                        <br/> Fluid Retention<br/>
                     </content>
                     <br/> Patients should be informed of the possibility of developing fluid retention (swelling, weight gain, dry cough, chest pain on respiration, or shortness of breath) and advised to seek medical attention promptly if those symptoms arise <content styleCode="italics">[see <linkHtml href="#Section_5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular Toxicity<br/>
                     </content>
                     <br/> Inform patients of the possibility of developing cardiovascular toxicity, including cardiac ischemic events, cardiac-related fluid retention, conduction abnormalities, and TIAs. Advise patients to seek immediate medical attention if symptoms suggestive of cardiovascular toxicity occur, such as chest pain, shortness of breath, palpitations, transient vision problems, or slurred speech <content styleCode="italics">[see <linkHtml href="#Section_5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.<br/>
                     <content styleCode="bold">
                        <br/> Pulmonary Arterial Hypertension</content>
                  </paragraph>
                  <paragraph>Inform patients of the possibility of developing pulmonary arterial hypertension (dyspnea, fatigue, hypoxia, and fluid retention) and advise them to seek medical attention promptly if those symptoms arise <content styleCode="italics">[see <linkHtml href="#Section_5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.<br/>
                     <content styleCode="bold">
                        <br/> Tumor Lysis Syndrome</content>
                  </paragraph>
                  <paragraph>Inform patients to immediately report and seek medical attention for any symptoms such as nausea, vomiting, weakness, edema, shortness of breath, muscle cramps, and seizures, which may indicate tumor lysis syndrome <content styleCode="italics">[see <linkHtml href="#Section_5.8">Warnings and Precautions (5.8)</linkHtml>]</content>.<br/>
                     <content styleCode="bold">
                        <br/> Growth and Development in Pediatric Patients<br/>
                     </content>
                     <br/> Inform pediatric patients and their caregivers of the possibility of developing bone growth abnormalities, bone pain, or gynecomastia and advise them to seek medical attention promptly if those symptoms arise <content styleCode="italics">[see <linkHtml href="#Section_5.10">Warnings and Precautions (5.10)</linkHtml>]</content>.<br/>
                     <content styleCode="bold">
                        <br/> Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Advise pregnant women of the potential risk to a fetus <content styleCode="italics">[see <linkHtml href="#Section_5.9">Warnings and Precautions (5.9)</linkHtml> and <linkHtml href="#Section_8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</item>
                     <item>Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with dasatinib and for 30 days after the last dose. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking dasatinib <content styleCode="italics">[see <linkHtml href="#Section_5.9">Warnings and Precautions (5.9)</linkHtml> and <linkHtml href="#Section_8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3)</linkHtml>].</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Lactation</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Advise women that breastfeeding is not recommended during treatment with dasatinib and for 2 weeks after the final dose <content styleCode="italics">[see <linkHtml href="#Section_8.2">Use in Specific Populations (8.2)</linkHtml>].</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Gastrointestinal Complaints<br/>
                     </content>
                     <br/> Inform patients that they may experience nausea, vomiting, or diarrhea with dasatinib. Advise patients to seek medical attention if these symptoms are bothersome or persistent. </paragraph>
                  <br/>
                  <paragraph>Advise patients using antacids to avoid taking dasatinib and antacids less than 2 hours apart <content styleCode="italics">[see <linkHtml href="#Section_7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Pain</content>
                  </paragraph>
                  <paragraph>Inform patients that they may experience headache or musculoskeletal pain with dasatinib. Advise patients to seek medical attention if these symptoms are bothersome or persistent.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Fatigue</content>
                  </paragraph>
                  <paragraph>Inform patients that they may experience fatigue with dasatinib. Advise patients to seek medical attention if this symptom is bothersome or persistent.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Rash</content>
                  </paragraph>
                  <paragraph>Inform patients that they may experience skin rash with dasatinib. Advise patients to seek medical attention if this symptom is bothersome or persistent.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Lactose<br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <br/>Inform patients that dasatinib contains 135 mg of lactose monohydrate in a 100 mg daily dose and 189 mg of lactose monohydrate in a 140 mg daily dose.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Hepatotoxicity<br/>
                     </content> </paragraph>
                  <paragraph>Advise patients that dasatinib can cause hepatotoxicity and that patients with previous history of liver diseases may be at risk. Advise patients to seek immediate medical attention if any symptoms suggestive of hepatotoxicity occur, such as abdominal pain, jaundice and scleral icterus, anorexia, bleeding, bruising, and dark-colored urine <content styleCode="italics">[see <linkHtml href="#Section_5.11">Warnings and Precautions (5.11)</linkHtml>]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Instructions for Taking Dasatinib<br/>
                        <br/>
                     </content>•   Missed Dose</paragraph>
                  <paragraph>Advise patients that if they miss a dose of dasatinib, they should take the next scheduled dose at its regular time. The patient should not take two doses at the same time.<br/>
                  </paragraph>
                  <paragraph>• Grapefruit Juice<br/>
                     <br/> Advise patients not to drink grapefruit juice as it may increase the amount of dasatinib in their blood and therefore increase their risk of adverse reactions.</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Aurobindo Pharma USA, Inc.<br/>
                     </content>279 Princeton-Hightstown Road<br/>East Windsor, NJ 08520<br/>
                     <br/> Manufactured by:<br/>
                     <content styleCode="bold">Eugia Pharma Specialities Limited <br/>
                     </content>Hyderabad - 500032<br/>India</paragraph>
               </text>
               <effectiveTime value="20240803"/>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_24">
               <id root="cd4c99e6-75fe-4bab-a84b-38ebb2e70f7c"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0" width="100%">
                     <colgroup>
                        <col width="100%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="middle">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>
                              <content styleCode="bold">Dasatinib Tablets</content>
                              <br/>
                              <content styleCode="bold">(da SAT in ib)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="top">
                              <content styleCode="bold">What are </content>
                              <content styleCode="bold">dasatinib tablets?</content>
                              <br/>Dasatinib tablets are a prescription medicine used to treat:<br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.</item>
                                 <item>adults with Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including imatinib.</item>
                                 <item>adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="top">
                              <content styleCode="bold">Before taking dasatinib tablets, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>have problems with your immune system</item>
                                 <item>have heart problems, including a condition called congenital long QT syndrome</item>
                                 <item>have low potassium or low magnesium levels in your blood</item>
                                 <item>have liver problems</item>
                                 <item>are lactose (milk sugar) intolerant</item>
                                 <item>are pregnant or plan to become pregnant. Dasatinib tablets can harm your unborn baby. </item>
                              </list>
                              <content styleCode="bold">        F</content>
                              <content styleCode="bold">emales who can become pregnant:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>You should not become pregnant during treatment with dasatinib tablets. </item>
                                 <item>You should use effective birth control (contraception) during treatment and for 30 days after your last dose of dasatinib tablets. </item>
                                 <item>Talk to your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with dasatinib tablets.</item>
                              </list>
                              <content styleCode="bold">         Males with female partners who can become pregnant:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>You should use effective birth control (contraception) during treatment and for 30 days after your last dose of dasatinib tablets. </item>
                                 <item>Your female partner should call her healthcare provider if she becomes pregnant or thinks she is pregnant during your treatment with dasatinib tablets.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if dasatinib passes into your breast milk. You should not breastfeed during treatment and for 2 weeks after your last dose of dasatinib tablets.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take, </content>including prescription and over-the-counter medicines, vitamins, antacids, and herbal supplements<content styleCode="bold">. If you take an antacid medicine, take it 2 hours before or 2 hours after your dose of </content>
                              <content styleCode="bold">dasatinib tablets</content>
                              <content styleCode="bold">.</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="top">
                              <content styleCode="bold">How should I take Dasatinib Tablets?</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take dasatinib tablets exactly as your healthcare provider tells you to take it.</item>
                                 <item>Your healthcare provider may change your dose of dasatinib tablets or temporarily stop treatment with dasatinib tablets. <content styleCode="bold">Do not change your dose or stop taking dasatinib tablets without first talking to your healthcare provider.</content>
                                 </item>
                                 <item>Take dasatinib tablets 1 time a day.</item>
                                 <item>Take dasatinib tablets with or without food, either in the morning or in the evening.</item>
                                 <item>Swallow dasatinib tablets whole. Do not crush, cut or chew the tablets. </item>
                                 <item>You should not drink grapefruit juice during treatment with dasatinib tablets.</item>
                                 <item>If you miss a dose of dasatinib tablets, take your next scheduled dose at your regular time. Do not take two doses at the same time.</item>
                                 <item>If you take too much dasatinib, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="top">
                              <content styleCode="bold">What are the possible side effects of </content>
                              <content styleCode="bold">d</content>
                              <content styleCode="bold">asatinib tablets?</content>
                              <br/>
                              <content styleCode="bold">D</content>
                              <content styleCode="bold">asatinib tablets may cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Low blood cell counts.</content> Low blood cell counts are common with dasatinib tablets and can be severe, including low red blood cell counts (anemia), low white blood cell counts (neutropenia), and low platelet counts (thrombocytopenia). Your healthcare provider will do blood tests to check your blood cell counts regularly during your treatment with dasatinib tablets. Call your healthcare provider right away if you have a fever or any signs of an infection during treatment with dasatinib tablets.</item>
                                 <item>
                                    <content styleCode="bold">Bleeding problems</content>. Bleeding problems are common with dasatinib tablets. Sometimes these bleeding problems can be serious and lead to death. Call your healthcare provider right away if you have:                 <list listType="unordered" styleCode="disc">
                                       <item>unusual bleeding or bruising of your skin</item>
                                       <item>bright red or dark tar-like stools</item>
                                       <item>decreased alertness, headache, or change in speech</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Your body may hold too much fluid (fluid retention). </content>Fluid retention is common with dasatinib tablets and can sometimes be severe. In severe cases, fluid may build up in the lining of your lungs, the sac around your heart, or your stomach cavity. Call your healthcare provider right away if you get any of these symptoms during treatment with dasatinib tablets:                 <list listType="unordered" styleCode="disc">
                                       <item>swelling all over your body</item>
                                       <item>weight gain</item>
                                       <item>shortness of breath, especially if this happens with low levels of physical activity or at rest </item>
                                       <item>dry cough</item>
                                       <item>chest pain when taking a deep breath </item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Heart and blood vessel (cardiovascular) problems.</content> Dasatinib tablets may cause heart problems, including an abnormal heart rate, a heart attack, or small strokes that last only a few minutes or a few hours, called transient ischemic attacks (TIAs). TIAs are often a warning sign that you are at risk for a more serious stroke. Your healthcare provider will monitor the potassium and magnesium levels in your blood and your heart function. </item>
                              </list>Get medical help right away if you develop any of the following symptoms during treatment with dasatinib tablets:<br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>chest pain</item>
                                 <item>shortness of breath</item>
                                 <item>feeling like your heart is beating too fast or you feel abnormal heart beats</item>
                                 <item>vision changes that may last for a short time</item>
                                 <item>slurred speech</item>
                                 <item>
                                    <content styleCode="bold">Pulmonary Arterial Hypertension (PAH).</content> Dasatinib tablets may cause high blood pressure in the vessels of your lungs. PAH may happen at any time during your treatment with dasatinib tablets. Your healthcare provider should check your heart and lungs before and during treatment with dasatinib tablets. Call your healthcare provider right away if you have shortness of breath, tiredness, or swelling all over your body (fluid retention).</item>
                                 <item>
                                    <content styleCode="bold">Severe skin reactions.</content> Dasatinib tablets may cause skin reactions that can sometimes be severe. Get medical help right away if you get a skin reaction with fever, sore mouth or throat, or blistering or peeling of your skin or in the mouth.</item>
                                 <item>
                                    <content styleCode="bold">Tumor Lysis Syndrome (TLS).</content> TLS is caused by a fast breakdown of cancer cells. TLS can cause you to have kidney failure and the need for dialysis treatment, and an abnormal heartbeat. Your healthcare provider may do blood tests to check you for TLS. Call your healthcare provider or get emergency medical help right away if you develop any of these symptoms during treatment with dasatinib tablets:<content styleCode="bold"/>
                                    <list listType="unordered" styleCode="disc">
                                       <item>nausea</item>
                                       <item>shortness of breath</item>
                                       <item>vomiting</item>
                                       <item>muscle cramps</item>
                                       <item>weakness</item>
                                       <item>seizures</item>
                                       <item>swelling<content styleCode="bold"/>
                                       </item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Slowing of growth and development in children.</content> Effects on bone growth and development in children have happened with dasatinib tablets and can sometimes be severe. Your healthcare provider will monitor your child’s bone growth and development during treatment with dasatinib tablets. Get medical help right away if your child develops bone pain.</item>
                                 <item>
                                    <content styleCode="bold">Liver problems. </content>Dasatinib tablets can cause liver problems. People who have had liver problems in the past may be at risk for getting liver problems with dasatinib tablets. Your healthcare provider will monitor your liver function as needed during the treatment with dasatinib. Call your healthcare provider or get medical help right away if you develop any symptoms of liver problems, including:<content styleCode="bold"> </content>
                                 </item>
                              </list>
                              <content styleCode="bold">          </content> •stomach-area (abdominal) pain                                          •bleeding<br/>                        •yellowing of your skin or white part of your eyes                 •bruising<br/>                        •loss of appetite                                                                     •dark “tea-colored” urine<br/>
                              <content styleCode="bold"/> <br/>The most common side effects of dasatinib tablets in adults receiving dasatinib tablets alone include:<br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>diarrhea </item>
                                 <item>tiredness </item>
                                 <item>headache </item>
                                 <item>nausea</item>
                                 <item>skin rash</item>
                                 <item>muscle pain</item>
                                 <item>shortness of breath </item>
                              </list>Dasatinib tablets may cause fertility problems in males and females. Talk to your healthcare provider if this is a concern for you.<br/>
                              <br/>             Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of dasatinib tablets.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<content styleCode="bold"/>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="top">
                              <content styleCode="bold">How should I store dasatinib tablets?</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store dasatinib tablets at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Ask your healthcare provider or pharmacist about the right way to throw away expired or unused dasatinib tablets.</item>
                                 <item>Wear latex or nitrile gloves when handling tablets that have accidentally been crushed or broken.</item>
                                 <item>Females who are pregnant should not handle crushed or broken dasatinib tablets.</item>
                              </list>
                              <content styleCode="bold">Keep </content>
                              <content styleCode="bold">dasatinib tablets</content>
                              <content styleCode="bold"> and all medicines out of the reach of children.</content>
                              <content styleCode="bold"/>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="top">
                              <content styleCode="bold"> General information about the safe and effective use of </content>
                              <content styleCode="bold">dasatinib tablets</content>
                              <content styleCode="bold">.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use dasatinib tablets for a condition for which it is not prescribed. Do not give dasatinib tablets to other people even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about dasatinib tablets that is written for health professionals.<content styleCode="bold"/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" align="justify" valign="top">
                              <content styleCode="bold"> What are the ingredients in </content>
                              <content styleCode="bold">dasatinib tablets</content>
                              <content styleCode="bold">?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient: </content>Dasatinib<br/>
                              <content styleCode="bold">Inactive ingredients: </content>croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose.<br/>
                              <br/>             The tablet coating consists of hypromellose, titanium dioxide and polyethylene glycol.<br/>
                              <content styleCode="italics">
                                 <br/>             Pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.<br/>
                              </content>
                              <br/>             Distributed by: <br/>
                              <content styleCode="bold">Aurobindo Pharma USA, Inc.</content>
                              <br/>279 Princeton-Hightstown Road<br/>East Windsor, NJ 08520<br/> <br/>Manufactured by:<br/>
                              <content styleCode="bold">Eugia Pharma Specialities Limited<br/>
                              </content>Hyderabad - 500032<br/>India<br/> <br/>For more information, call Aurobindo Pharma USA, Inc. at 1-866-850-2876. <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> This Patient Information has been approved by the U.S. Food and Drug Administration. <br/>
                     <br/> Revised: August 2024</paragraph>
               </text>
               <effectiveTime value="20240803"/>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="85b56c10-617f-45a0-aee1-b07a877bfa10"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg (60 Tablets Bottle)</title>
               <text>
                  <paragraph>NDC 59651-542-60 <br/>
                     <br/>
                     <content styleCode="bold">Dasatinib Tablets <br/> 20 mg <br/>
                        <br/> Rx only                 60 Tablets <br/>
                        <br/> Do not crush, cut or chew tablets. <br/> Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO</content>
                  </paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg (60 Tablet Bottle)</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_35">
               <id root="1920d438-b90d-4ca4-8437-b82a738c01ab"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg 15 (1x15) Unit-dose Tablets</title>
               <text>
                  <paragraph>NDC 59651-542-15 <br/>
                     <br/>
                     <content styleCode="bold">Rx only <br/> Dasatinib Tablets <br/> 20 mg <br/>
                        <br/> Do not crush, cut or chew tablets. Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO         15 (1 x 15) Unit-dose Tablets</content>
                  </paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg 15 (1x15) Unit-dose Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_26">
               <id root="c0642f92-1be9-4002-a987-8f18024e1be9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg (60 Tablets Bottle)</title>
               <text>
                  <paragraph>NDC 59651-543-60 <br/>
                     <br/>
                     <content styleCode="bold">Dasatinib Tablets <br/> 50 mg <br/>
                        <br/> Rx only                         60 Tablets <br/>
                        <br/> Do not crush, cut or chew tablets. <br/> Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg (60 Tablet Bottle)</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_25">
               <id root="4641e5ea-b0a9-4f64-b9c9-05d552008791"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg 15 (1x15) Unit-dose Tablets</title>
               <text>
                  <paragraph>NDC 59651-543-15 <br/>
                     <br/>
                     <content styleCode="bold">Rx only <br/> Dasatinib Tablets <br/> 50 mg <br/>
                        <br/> Do not crush, cut or chew tablets. Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO         15 (1 x 15) Unit-dose Tablets</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg 15 (1x15) Unit-dose Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_27">
               <id root="0339c047-0f96-4328-be0c-c31912269eca"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 70 mg (60 Tablets Bottle)</title>
               <text>
                  <paragraph>NDC 59651-544-60 <br/>
                     <br/>
                     <content styleCode="bold">Dasatinib Tablets <br/> 70 mg <br/>
                        <br/> Rx only                     60 Tablets <br/>
                        <br/> Do not crush, cut or chew tablets. <br/> Swallow tablets whole</content>. <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM6"/>
                  <br/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 70 mg (60 Tablet Bottle)</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_28">
               <id root="a0e16c08-a839-4cc9-b41d-2fa608b837cc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 70 mg 15 (1x15) Unit-dose Tablets</title>
               <text>
                  <paragraph>NDC 59651-544-15 <br/>
                     <br/>
                     <content styleCode="bold">Rx only <br/> Dasatinib Tablets <br/> 70 mg <br/>
                        <br/> Do not crush, cut or chew tablets. Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO         15 (1 x 15) Unit-dose Tablets</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 70 mg 15 (1x15) Unit-dose Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_29">
               <id root="96c0c95d-f469-45f7-aa3e-cb56d882976d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 80 mg (30 Tablets Bottle)</title>
               <text>
                  <paragraph>NDC 59651-545-30<br/>
                     <br/>
                     <content styleCode="bold">Dasatinib Tablets <br/> 80 mg <br/>
                        <br/> Rx only                     30 Tablets <br/>
                        <br/> Do not crush, cut or chew tablets. <br/> Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM8"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 80 mg (30 Tablet Bottle)</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_30">
               <id root="50cc5e5d-35a2-414f-b404-8573ac231618"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 80 mg 15 (1x15) Unit-dose Tablets</title>
               <text>
                  <paragraph>NDC 59651-545-15 <br/>
                     <br/>
                     <content styleCode="bold">Rx only <br/> Dasatinib Tablets <br/> 80 mg <br/>
                        <br/> Do not crush, cut or chew tablets. Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO             15 (1 x 15) Unit-dose Tablets</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM9"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 80 mg 15 (1x15) Unit-dose Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_31">
               <id root="c069a16a-1b25-4599-9e19-2c655de9bcf0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg (30 Tablets Bottle)</title>
               <text>
                  <paragraph>NDC 59651-546-30<br/>
                     <br/>
                     <content styleCode="bold">Dasatinib Tablets <br/> 100 mg <br/>
                        <br/> Rx only                     30 Tablets <br/>
                        <br/> Do not crush, cut or chew tablets. <br/> Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM10"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg (30 Tablet Bottle)</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_32">
               <id root="f99e30b3-caa0-43c2-b048-3eef185a3dd5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg 15 (1x15) Unit-dose Tablets</title>
               <text>
                  <paragraph>NDC 59651-546-15 <br/>
                     <br/>
                     <content styleCode="bold">Rx only <br/> Dasatinib Tablets <br/> 100 mg <br/>
                        <br/> Do not crush, cut or chew tablets. Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO         15 (1 x 15) Unit-dose Tablets</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM11"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg 15 (1x15) Unit-dose Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_33">
               <id root="5e559687-d8f4-42e7-b91b-c25938455eb9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 140 mg (30 Tablets Bottle)</title>
               <text>
                  <paragraph>NDC 59651-547-30 <br/>
                     <br/>
                     <content styleCode="bold">Dasatinib Tablets <br/> 140 mg <br/>
                        <br/> Rx only                     30 Tablets <br/>
                        <br/> Do not crush, cut or chew tablets. <br/> Swallow tablets whole. <br/>
                     </content>
                     <br/>
                     <content styleCode="bold">AUROBINDO</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM12"/>
                  <br/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM12">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 140 mg (30 Tablet Bottle)</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_34">
               <id root="08818da1-fb49-4d3c-bb6e-6b140f61f1b6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 140 mg 15 (1x15) Unit-dose Tablets</title>
               <text>
                  <paragraph>NDC 59651-547-15 <br/>
                     <br/>
                     <content styleCode="bold">Rx only <br/> Dasatinib Tablets <br/> 140 mg <br/>
                        <br/> Do not crush, cut or chew tablets. Swallow tablets whole.</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">AUROBINDO                         15 (1 x 15) Unit-dose Tablets</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM13"/>
               </text>
               <effectiveTime value="20240803"/>
               <component>
                  <observationMedia ID="MM13">
                     <text>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 140 mg 15 (1x15) Unit-dose Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dasatinib-fig12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>